ID

40002

Description

Standard Data Tabulation Model (SDTM) by the Clinical Data Interchange Standards Consortium (CDISC) Based on SDTM v1.7 and the implementation guide SDTMIG v3.3 (for human clinical trials). Quote from https://www.cdisc.org/standards/foundational/sdtmig: "Where the SDTM provides a standard model for organizing and formatting data for human and animal studies, the SDTMIG is intended to guide the organization, structure, and format of standard clinical trial tabulation datasets. It was developed to support data submitted to a regulatory authority, such as the US Food and Drug Administration (FDA), but is not restricted to use in regulated submissions. SDTM is one of the required standards that sponsors must use as specified in the FDA’s Data Standards Catalog (see section II.C) for NDA, ANDA, and certain BLA submissions effective December 2016. For more information, please visit the Guidance on Standardized Data." Domains and Items from other implementation guides (e.g. SDTM-PGx, SDTM-MD) are not included. Please refer to CDISC for information on the implementation of SDTM and associated CDISC standards, do not rely solely on this adaption of CDISC standards. Codelists from the SDTM Terminology included as far as possible in this general version of SDTM (e.g. in the Findings About Domain they are not included, as they depend on the test/result/domain, they are associated with, e.g. COPD Findings About, Cardiovascular Findings About, ...; other test-specific codelists from other domains). Included are the complete codelists referenced in SDTM v1.7 or SDTMIG v3.3, they may need to be constrained depending on the domain or the specific use case. Codelists taken from NCI page https://www.cancer.gov/research/resources/terminology/cdisc in November 2019. CDISC Intellectual Property Policy Version 1.1 (August 15th 2014) Purpose: In its role of leading the development of standards, CDISC must protect those standards to ensure that, to the extent practicable, they remain neutral, open, compensation (royalty)-free, and without encumbering ties to prior intellectual property. This Intellectual Property Policy (“Policy”) is designed to facilitate the activities of CDISC in promotion of such open Standards, to maximize the adoption of such Standards by protecting against the ownership of such Standards by one party and to protect the legitimate intellectual property rights of Contributors.This Policy ensures that CDISC is in accordance with its Bylaws, other Policies and basic Principles.For more information on CDISC, its Bylaws, Strategic Plan, other Policies and basic Principles, please see the CDISC website at www.cdisc.org. Definitions: 2.1“Affiliate” means any entity that directly or indirectly controls, is controlled by, or is under common control with, another entity, so long as such control exists. “Control” means direct or indirect beneficial ownership of or the right to exercise (a) more than fifty percent (50%) of the voting stock or equity in an entity; or (b) more than fifty percent (50%) of the relevant ownership interest or decision-making authority representing the right to make the decisions for the subject entity in the event that there is no voting stock or equity. In the event such control ceases to exist, such Affiliate will be deemed to have withdrawn as a Member, pursuant to the terms set forth in the withdrawal provisions in Section 8. 2.2“CDISC Group” means any CDISC “Working Team,” “Support Team,” “Task Force,” technical working group, or sub-group of a CDISC team or group. 2.3“Contribution” means any material, suggestion, or other submission offered by a Participant in the process of developing a Draft Standard or Final Standard for the purpose of incorporating such submission into a Final Standard, provided that such submission either (a) exists in a tangible form of expression (including in electronic media); or (b) is a verbal statement that is memorialized in written documentation (such as meeting minutes or a draft standard) and is either confirmed or not objected to by such Participant within fifteen (15) calendar days after its receipt of such memorialization. 2.4“Draft Standard” means any CDISC standard or specification developed by a CDISC Group, prior to adoption and publication as a Final Standard. 2.5“Final Standard” means any CDISC standard adopted and published by CDISC as a Final (production version) Standard. 2.6“Licensee’s Product(s)” means only those specific portions of products (software, tools, data formats, other products or combinations thereof), not the product as a whole, that implement and are compliant with the relevant Required Portions of a Final Standard. 2.7 “Member” means all classes of CDISC membership as set forth in CDISC documentation and their Affiliates, including Corporate Benefactors, Corporate Sponsors, Corporate Members and Associate Members. 2.8“Necessary Claims” means those claims in any patent or patent application in any jurisdiction in the world, excluding design patents and design registrations, that would necessarily be infringed by an implementation of those portions of a particular Final Standard within the scope of the CDISC Group charter in effect at the time such Final Standard was developed. A patent claim is “necessarily infringed” only when it is not possible to avoid infringing it because there is no commercially reasonable, non-infringing alternative for implementing the Required Portions of such Final Standard. Notwithstanding the foregoing, Necessary Claims do not include any claims: (i) that may be contained in the same patent as Necessary Claims but are not themselves Necessary Claims; (ii) that cover solely any portions of any product and any combinations thereof that are not required for compliance with the Final Standard; (iii) that cover any enabling technologies that may be necessary to make or use any product or portion thereof that complies with a Final Standard, but are not themselves expressly set forth in the Final Standard (e.g., semiconductor manufacturing technology, compiler technology, object oriented technology, operating system technology, computers, networks, connectivity protocols, or the like); (iv) that cover implementation examples or reference implementations in the text of a Final Standard; or (v) that cover the implementation of other published specifications/standards developed elsewhere and merely referred to in the body of a Final Standard.Since this definition of Necessary Claims focuses solely on Final Standards, not Draft Standards, for purposes of applying the disclosure obligations in Section 5 of this Policy, references to disclosures of Non-Contributed Necessary Claims “covering a Draft Standard” shall be understood to assume that the Draft Standard at issue would ultimately be adopted, without modification, as a Final Standard. 2.9 “Non-Contributed Necessary Claims” means those Necessary Claims that cover not a Participant’s own Contribution but either: (a) the Contribution of another party; or (b) material that is otherwise included in a Final Standard. 2.10 “Participant” means any party that: (1) formally joins a CDISC Group as a listedparticipant; or (2) makes a Contribution to a CDISC Group; or (3) attends one (1) or more meeting(s)/teleconference(s) of a CDISC Group (in person or by telephone) within a one-year period. Participants and other parties must sign (either in writing or electronically) the document attached to this Policy as Attachment A before formally joining, taking part in, or making a Contribution to each particular CDISC Group. Note: A Participant may be an individual acting in its own individual capacity or an organization, and may or may not be a CDISC Member organization or from a CDISC Member organization. If the Participant is an organization, the Participant may be represented in CDISC Groups by a Representative. 2.11“Representative” means an individual who is identified to CDISC as having authority to participate in CDISC or a CDISC Group on behalf of the Participant organization by which s/he is employed. The actions and statements of such individual(s) will be deemed to legally bind such Representative’s Participant organization and its affiliates. 2.12“Required Portion” means a portion of a Final Standard that is required for an implementation to comply with a Final Standard (also known as a “normative” or “mandatory” portion), but not including any elements that are required solely for conformance with any optional (i.e., “non-normative,” “non-mandatory”) portion(s) of a Final Standard; provided, however, that where a Final Standard contains a choice of two or more portions, and implementing any one of the portions is required to comply with the Final Standard (i.e., mutually exclusive required options), each such portion shall be deemed to be a Required Portion. 3 Compensation-free Patent License Commitment Each Participant agrees that, upon request and subject to Sections 5.1 and 8, it will grant, to all parties implementing a Final Standard developed by a CDISC Group in which it was a Participant, a nonexclusive, compensation-free (i.e., no royalty or other fee), nontransferable, non-sublicensable, worldwide, and otherwise reasonable and non-discriminatory license under such Participant’s Necessary Claims covering such Final Standard, solely to make, have made, use, import, offer to sell, sell, lease, and otherwise distribute and dispose of Licensee’s Products that implement such Final Standard; provided, however, that such commitment to license shall not apply to any Necessary Claims for which the Participant does not have the right to license without obligation of payment of royalties or other material consideration by such Participant to an unaffiliated third party. The commitment to license arising under this Section shall be effective as of the date the party was first deemed to be a Participant in the applicable CDISC Group. 4 Copyright Ownership and Licenses 4.1Copyright Ownership in Final Standards. CDISC shall own the copyright in Final Standards developed by CDISC, subject to the underlying copyright rights of the contributing Participants and other copyright owners. Any publication of a Final Standard shall contain an appropriate copyright notice in the name of CDISC. 4.2Copyright License for Contributions. Upon submitting a Contribution, each contributing Participant grants and agrees to grant (i) to each Participant a non-exclusive, worldwide, perpetual, nontransferable, compensation-free license under the Participant’s copyright rights in the Contribution to reproduce, publish, display, perform, distribute, and create derivative works of the Contribution, solely for the purpose of creating and promoting the Draft Standard and Final Standard for which such Contribution was submitted, and (ii) to CDISC a non-exclusive, worldwide, perpetual, irrevocable, compensation-free license to reproduce, publish, display, perform, distribute, and create derivative works of such Contribution (including any Draft Standard, Final Standard, or portion or derivative thereof incorporating the Contribution), and to freely sublicense such rights through multiple tiers, for the purpose of creating and promoting the Draft Standard and Final Standard and for other CDISC activities. Upon the adoption of a Final Standard, CDISC hereby grants and agrees to grant to all Participants and without limiting the generality of the licenses granted herein is also authorized to grant to other parties a nonexclusive, compensation-free, non-transferable, non-sublicensable, worldwide, perpetual, copyright license to reproduce, publish, display, perform, and distribute the Final Standard solely for the purpose of creating and distributing a Licensee’s Product(s) and any accompanying documentation. CDISC may also sublicense such copyright rights to reproduce, publish, display, perform, and distribute the Final Standard to another standard development organization solely for the purpose of adopting the same standard, subject to the relevant CDISC approval procedures, if any, for such further distribution by other organizations as may be established by the CDISC Board of Directors. All reproductions of a Draft Standard or Final Standard shall include all copyright notices, disclaimers, limitations of liability, and other such statements contained in the original. 5 Treatment of Non-Contributed Necessary Claims 5.1Review Period / Licensing Obligations for Non-Contributed Necessary Claims. To ensure that all Participants have the opportunity to review each proposed Draft Standard as a complete document for purposes of identifying Non-Contributed Necessary Claims, CDISC shall, at least thirty (30) calendar days prior to the finalization of the Draft Standard, notify all Participants via e-mail and post the Draft Standard on the CDISC website for open review. During the review period, each Participant in the CDISC Group that developed the Draft Standard under review (as well as others that choose to take part in such review) shall: (a) review the Draft Standard; (b) disclose, pursuant to Section 5.2, any of its Non-Contributed Necessary Claim(s) covering such Draft Standard that the Participant is not willing to license to all implementers of the resulting Final Standard under the compensation-free and otherwise reasonable and non-discriminatory commitment of Section 3; and (c) submit, prior to the end of the review period, a written licensing declaration for any Non-Contributed Necessary Claim disclosed under subclause (b) indicating whether the Participant will commit to license such disclosed claim(s) at least on reasonable and non-discriminatory (“RAND”) terms and conditions (note, Necessary Claims that cover one’s own Contributions must be licensed compensation-free pursuant to Section 3). If a Participant declares its intent under subclause (c) to license the disclosed Non-Contributed Necessary Claim on a RAND basis, it will have a RAND licensing obligation for such disclosed claim to all implementers of the Final Standard. If instead the Participant declares its intent under subclause (c) not to commit to at least RAND licensing for such disclosed claim and withdraws prior to the end of the review period, such Participant will have no licensing obligation for such disclosed claim. If, however, the Participant fails to comply with either of these two options, it will be deemed to have committed to the compensation-free and otherwise reasonable and non-discriminatory licensing obligation of Section 3 (“Default Licensing Obligation”) for such disclosed claim. Any other Non-Contributed Necessary Claims of such Participants that were not disclosed prior to the end of the review period shall also be subject to the Default Licensing Obligation. For the avoidance of doubt, the Default Licensing Obligation (which obligation actually arose under Section 3 and which the Participant failed to avoid by complying with the disclosure/licensing declaration and (if applicable) withdrawal provvisions of this Section) applies to all of a Partticipant’s undisclosed Non-Contributed Necessary Claims covering the Final Standard ultimately resulting from the Draft Standard under review, despite the lack of actual and personal knowledge thereof by any individual Representative who participates in such CDISC Group on behalf of such Participant. In the event that a Participant discloses its intention not to make at least a RAND licensing commitment for certain of its Non-Contributed Necessary Claims, the CDISC Group that developed the affected Draft Standard will, in consultation with the CDISC Board of Directors, determine how best to proceed, such as by attempting to develop a revised version of the Draft Standard that works around the potentially blocking patent claims. If, after the review period ends, a Draft Standard is substantially modified, a subsequent review period shall be conducted, under the terms of Section 5.1, before the revised Draft Standard is adopted and published as a Final Standard. 5.2Minimum Contents of Disclosure. With respect to Non-Contributed Necessary Claims in issued patents and published patent applications subject to disclosure under Section 5.1, a Participant must disclose, at a minimum, the identity of the patent rights holder and/or applicant and the patent number or application number. With respect to unpublished patent applications subject to disclosure under Section 5.1, a Participant must disclose, at a minimum, the existence of the application containing the asserted Non-Contributed Necessary Claim(s) and identify the portion(s) of the Draft Standard on which such asserted claim(s) read(s), but need not disclose identifying information (e.g., application number, application contents). Nothing herein precludes broader disclosure of unpublished patent applications on a voluntary basis or pursuant to a non-disclosure agreement. If any disclosed patent or patent application contains Necessary Claims which, if licensed, would require a payment of royalties or other material consideration to an unaffiliated third party, the Participant must also highlight this fact in its disclosure statement. Nothing in this Section or this Policy imposes any duty on any Representative or Participant to perform a patent search or other search of intellectual property portfolios. 6 CDISC Processes; Statement Regarding Patent Disclosures and Other Issues 6.1CDISC Records of Patent Disclosures / Licensing Declarations. The CDISC President shall promptly provide to the CDISC Board of Directors, in writing, the information contained in any patent disclosure. CDISC shall maintain a file, accessible by the public, which includes all patent disclosure statements and licensing declarations received for any Draft Standard or Final Standard. CDISC shall also provide such information to any party, upon request, in order to facilitate such party’s ability to seek and obtain all known patent licenses necessary to implement a Final Standard in a Licensee’s Product. 6.2CDISC Patent Disclaimers. After CDISC’s adoption of the CDISC IP Policy,all published Final Standards shall include the following disclaimers (or their equivalent):“It is possible that implementation of and compliance with this standard may require use of subject matter covered by patent rights. By publication of this standard, no position is taken with respect to the existence or validity of any claim or of any patent rights in connection therewith. CDISC, including the CDISC Board of Directors, shall not be responsible for identifying patent claims for which a license may be required in order to implement this standard or for conducting inquiries into the legal validity or scope of those patents or patent claims that are brought to its attention.”In addition, when CDISC receives from a patent rights holder a written licensing declaration indicating that a license will be required from such patent rights holder by implementers of a Final Standard, then such published Final Standard shall also add the following statement to the end of the above disclaimer:“Certain patent rights holders have filed a statement of willingness to grant a patent license to all implementers of this standard, consistent with the requirements of the CDISC Intellectual Property Policy. CDISC, including the CDISC Board of Directors, makes no representation as to the reasonableness of any terms or conditions of the license agreements offered by such patent rights holders, and all negotiations regarding such terms and conditions must take place between the individual parties outside the context of CDISC. Further information regarding those parties who have claimed patent rights in the standard and expressed their willingness to provide a license may be obtained from the CDISC President. The user should be aware, however, that it is also possible that other patent rights that have not been disclosed to CDISC may be implicated by implementation of or compliance with the standard.” 6.3CDISC Statements Regarding General Disclaimers, Limitation of Liability, and Copyright License to End Users. All published Final Standards shall also include statements of warranty, disclaimer, and limitation of liability statements substantially similar to those in Section 9.4 and Section 9.5, as well as a copyright notice to end users consistent with Section 1. 7 ConfidentialityAll Contributions and information disclosed as a part of CDISC activities shall be deemed non-confidential, and neither CDISC nor any Participant or Representative assumes any confidentiality obligations. 8 Withdrawal/Termination 8.1A Participant may withdraw from CDISC, or from any CDISC Group, at any time by sending a written notice to CDISC. Withdrawal shall be effective upon receipt of such written notice by CDISC. 8.2Effect of Withdrawal/Termination. Notwithstanding the Participant’s withdrawal or termination, and except (as applicable) as provided in Section 5.1 or Section 8.3, a Participant’s agreement to grant a license under Section 3 or Section 5.1 (as applicable) shall remain in full force and effect for: (1) Necessary Claims covering a Contribution made by the withdrawing/terminating Participant that is incorporated into a Final Standard to which such Contribution was offered (even if such Final Standard is adopted after such Participant’s withdrawal/termination); or (2) Non-Contributed Necessary Claims covering a Final Standard as such Final Standard (or the Draft Standard from which it arose) existed on the date of withdrawal/termination (even if such Final Standard is adopted after such Participant’s withdrawal/termination); and (3) Necessary Claims covering a Final Standard adopted by CDISC after the effective date of the Participant’s withdrawal/termination that: (i) are necessary for the later-adopted Final Standard to be backwards compatible with a prior Final Standard; and (ii) are used in a substantially similar manner, extent, and result as such Necessary Claims were used in such prior Final Standard for which the Participant is obligated to grant licenses. All rights and obligations of the withdrawn/terminated Participant other than those specifically referenced in this Section 8.2 or Section 3, 5.1, or 4.2 shall cease upon such withdrawal/termination. 9 General 9.1 No Other Licenses. Except for the rights expressly provided under this Policy, neither CDISC nor any Participant grants or receives, by implication, estoppel, or otherwise, any rights under any patents, copyrights, or other intellectual property rights. 9.2 No Software Code in Required Portions of Standards. Except for data interchange formats, no Draft Standard or Final Standard, and no Contribution, may include software code (i.e., source code or object code), except for code that will be used for illustrative purposes only and will not be deemed to be a Required Portion of a Draft Standard or Final Standard. 9.3 Representations and Warranties. Each Participant shall be deemed to represent, warrant, and covenant, at the time of a Contribution by such Participant (or by its Representative), that to the best of its knowledge and ability: (a) it holds or has the right to grant all relevant licenses to any of its Contributions in all jurisdictions or territories in which it holds relevant intellectual property rights; (b) there are no limits to the Participant’s ability to make the grants, acknowledgments, and agreements herein; and (c) the Contribution does not subject any Contribution, Draft Standard, Final Standard, or implementations thereof, in whole or in part, to licensing obligations with additional restrictions or requirements inconsistent with those set forth in this Policy, or that would require any such Contribution, Final Standard, or implementation, in whole or in part, to be either: (i) disclosed or distributed in source code form; (ii) licensed for the purpose of making derivative works (other than as set forth in Section 4.2); or (iii) distributed at no charge, except as set forth in Sections 3, 5.1, and 4.2. If a Participant has knowledge that a Contribution made by any Participant or any other party may subject any Contribution, Draft Standard, Final Standard, or implementation, in whole or in part, to one or more of the licensing obligations listed in Section 9.3, such Participant shall give prompt notice of the same to the CDISC President who shall promptly notify all Participants. 9.4 No Other Warranties/Disclaimers. ALL PARTICIPANTS ACKNOWLEDGE THAT, EXCEPT AS PROVIDED UNDER SECTION 9.3, ALL DRAFT STANDARDS AND FINAL STANDARDS, AND ALL CONTRIBUTIONS TO FINAL STANDARDS AND DRAFT STANDARDS, ARE PROVIDED “AS IS” WITH NO WARRANTIES WHATSOEVER, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, AND THE PARTICIPANTS, REPRESENTATIVES , THE CDISC PRESIDENT, THE CDISC BOARD OF DIRECTORS, AND CDISC EXPRESSLY DISCLAIM ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR ANY PARTICULAR OR INTENDED PURPOSE, OR ANY OTHER WARRANTY OTHERWISE ARISING OUT OF ANY PROPOSAL, FINAL STANDARDS OR DRAFT STANDARDS, OR CONTRIBUTION. 9.5 Limitation of Liability . IN NO EVENT WILL CDISC OR ANY OF ITS CONSTITUENT PARTS (INCLUDING, BUT NOT LIMITED TO, THE CDISC BOARD OF DIRECTORS, THE CDISC PRESIDENT, CDISC STAFF, AND CDISC MEMBERS) BE LIABLE TO ANY OTHER PERSON OR ENTITY FOR ANY LOSS OF PROFITS, LOSS OF USE, DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES, WHETHER UNDER CONTRACT, TORT, WARRANTY, OR OTHERWISE, ARISING IN ANY WAY OUT OF THIS POLICY OR ANY RELATED AGREEMENT, WHETHER OR NOT SUCH PARTY HAD ADVANCE NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. 9.6 Publicity. Each Participant consents to the public disclosure and use of its name for purposes of publicly promoting Final Standards, including the use in statements regarding the compliance of the Participant’s Licensee’s Products with a Final Standard, unless such Participant explicitly indicates in writing to the CDISC President such Participant’s refusal to consent to such public disclosure and use of its name. 9.7 Governing Law / Jurisdiction / Venue. This Policy shall be construed and controlled by the laws of the State of Delaware without giving effect to conflict-of-law principles. The parties agree that all disputes arising in any way out of this Policy will be heard exclusively in, and all parties irrevocably consent to jurisdiction and venue in, the state and Federal courts of the State of Delaware. 9.8 Complete Agreement. This Policy (including all documents referenced herein) sets forth the entire understanding between CDISC and its Members and Participants and Representatives regarding the treatment of patent, copyright, and related issues and supersedes all prior agreements, representations, and understandings related thereto. 10 AuthorizationThis document has been approved and is in effect on this date: Name CDISC Board of Directors Date 11 Change ControlThis Policy is the complete and exclusive statement of the Clinical Data Interchange Standards Consortium, Inc.’s (“CDISC”) Intellectual Property policy, consistent with the CDISC Bylaws. Once this Policy has been approved by the CDISC Board of Directors, it will apply to Members and other parties to the extent they are Participants in one or more CDISC Groups. Any future revisions to this Policy (or any document referenced herein) will become effective only upon approval of such revisions by the CDISC Board and only after: (a) CDISC notifies all Members and Participants in writing (such as by e-mail) of such revisions; (b) a clear and conspicuous link to the revised Policy, with the revisions highlighted, is posted on the home page of the CDISC website (currently http://www.cdisc.org/) for all existing Members/Participants and potential new Members/Participants to see; and (c) Participants are afforded at least thirty (30) calendar days from the date of receiving notice of such revisions to withdraw from CDISC or from particular CDISC Groups; provided, however, that ministerial changes to this Policy, such as proofreading corrections or formatting changes, may be executed by the CDISC Board and, upon CDISC Board approval, shall be immediately effective as to all existing and new Participants, so long as a revised version of the Policy containing such ministerial changes is posted on the home page of the CDISC website. Any Participant that withdraws from CDISC or from a CDISC Group prior to the end of this thirty (30)-day period will be subject to the version of the Policy that was in effect prior to the Board-approved revisions, in accordance with its terms and the withdrawal provisions of such version, but will not be subject to new or revised terms of the revised Policy. Any existing Participant that does not so withdraw prior to the end of this thirty (30)-day period will be deemed to have ratified and accepted the revised Policy in its entirety even without written agreement to such revised Policy by such Participant.

Link

https://www.cdisc.org/standards/foundational/sdtmig

Keywords

  1. 3/9/20 3/9/20 -
  2. 11/5/20 11/5/20 -
  3. 4/13/21 4/13/21 - Dr. rer. medic Philipp Neuhaus
  4. 6/18/21 6/18/21 - Sarah Riepenhausen
  5. 6/21/21 6/21/21 - Sarah Riepenhausen
  6. 9/20/21 9/20/21 -
  7. 9/27/21 9/27/21 -
Copyright Holder

CDISC

Uploaded on

March 9, 2020

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

CDISC SDTM

Observation Class: Interventions - Domain: Concomitant/Prior Medications

  1. StudyEvent: ODM
    1. Observation Class: Special Purpose - Domain: Comments
    2. Observation Class: Special Purpose - Domain: Demographics
    3. Observation Class: Special Purpose - Domain: Subject Elements
    4. Observation Class: Special Purpose - Domain: Subject Disease Milestones
    5. Observation Class: Special Purpose - Domain: Subject Visits
    6. Observation Class: Interventions - Domain: Procedure Agents
    7. Observation Class: Interventions - Domain: Concomitant/Prior Medications
    8. Observation Class: Interventions - Domain: Exposure
    9. Observation Class: Interventions - Domain: Exposure as Collected
    10. Observation Class: Interventions - Domain: Meal Data
    11. Observation Class: Interventions - Domain: Procedures
    12. Observation Class: Interventions - Domain: Substance Use
    13. Observation Class: Events - Domain: Adverse Events
    14. Observation Class: Events - Domain: Clinical Events
    15. Observation Class: Events - Domain: Disposition
    16. Observation Class: Events - Domain: Protocol Deviations
    17. Observation Class: Events - Domain: Healthcare Encounters
    18. Observation Class: Events - Domain: Medical History
    19. Observation Class: Findings - Domain: Drug Accountability
    20. Observation Class: Findings - Domain: Death Details
    21. Observation Class: Findings - Domain: ECG Test Results
    22. Observation Class: Findings - Domain: Inclusion/Exclusion Criteria Not Met
    23. Observation Class: Findings - Domain: Immunogenicity Specimen Assessments
    24. Observation Class: Findings - Domain: Laboratory Test Results
    25. Observation Class: Findings - Domain: Microbiology Specimen
    26. Observation Class: Findings - Domain: Microbiology Susceptibility
    27. Observation Class: Findings - Domain: Microscopic Findings
    28. Observation Class: Findings - Domain: Morphology
    29. Observation Class: Findings - Domain: Cardiovascular System Findings
    30. Observation Class: Findings - Domain: Musculoskeletal System Findings
    31. Observation Class: Findings - Domain: Nervous System Findings
    32. Observation Class: Findings - Domain: Ophthalmic Examinations
    33. Observation Class: Findings - Domain: Reproductive System Findings
    34. Observation Class: Findings - Domain: Respiratory System Findings
    35. Observation Class: Findings - Domain: Urinary System Findings
    36. Observation Class: Findings - Domain: Pharmacokinetics Concentrations
    37. Observation Class: Findings - Domain: Pharmacokinetics Parameters
    38. Observation Class: Findings - Domain: Physical Examination
    39. Observation Class: Findings - Domain: Functional Tests
    40. Observation Class: Findings - Domain: Questionnaires
    41. Observation Class: Findings - Domain: Disease Response and Clin Classification
    42. Observation Class: Findings - Domain: Subject Characteristics
    43. Observation Class: Findings - Domain: Subject Status
    44. Observation Class: Findings - Domain: Tumor/Lesion Identification
    45. Observation Class: Findings - Domain: Tumor/Lesion Results
    46. Observation Class: Findings - Domain: Vital Signs
    47. Observation Class: Findings - Domain: Findings About Events or Interventions
    48. Observation Class: Findings - Domain: Skin Response
    49. Observation Class: Trial Design - Domain: Trial Arms
    50. Observation Class: Trial Design - Domain: Trial Elements
    51. Observation Class: Trial Design - Domain: Trial Visits
    52. Observation Class: Trial Design - Domain: Trial Disease Assessments
    53. Observation Class: Trial Design - Domain: Trial Disease Milestones
    54. Observation Class: Trial Design - Domain: Trial Inclusion/Exclusion Criteria
    55. Observation Class: Trial Design - Domain: Trial Summary Information
    56. Observation Class: Relationships - Domain: Related Records
    57. Observation Class: Relationships - Domain: Supplemental Qualifiers for [domain name]
    58. Observation Class: Relationships - Domain: Related Subjects
    59. Observation Class: Study Reference - Domain: Non-host Organism Identifiers
Concomitant/Prior Medications
Description

Concomitant/Prior Medications

Alias
SDTMIG v3.3
CM
UMLS CUI-1
C2347852
UMLS CUI-2
C2826257
NCIt V19.10d:
C49568
Study Identifier
Description

Role: Identifier CDISC Notes (for domains) Description (for General Classes): Unique identifier for a study. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1]
C2826693
SDTMIG 3.3
STUDYID
NCIt V19.10d
C83082
Domain Abbreviation
Description

Role: Identifier CDISC Notes (for domains) Description (for General Classes): Two-character abbreviation for the domain. Controlled Terms or Format (if applicable): CM

Data type

text

Alias
UMLS CUI [1,1]
C1883204
UMLS CUI [1,2]
C0000723
SDTMIG 3.3
DOMAIN
NCIt V19.10d
C49556
Unique Subject Identifier
Description

Role: Identifier CDISC Notes (for domains) Description (for General Classes): Identifier used to uniquely identify a subject across all studies for all applications or submissions involving the product. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C1710548
UMLS CUI [1,2]
C2826693
SDTMIG 3.3
USUBJID
NCIt V19.10d
C70731
Sequence Number
Description

Role: Identifier CDISC Notes (for domains) Description (for General Classes): Sequence number to ensure uniqueness of subject records within a domain. May be any valid number. Controlled Terms or Format (if applicable): NA

Data type

integer

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C2348184
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C2348184
SDTMIG 3.3
CMSEQ
NCIt V19.10d
C83233
Group ID
Description

Role: Identifier CDISC Notes (for domains) Description (for General Classes): Used to tie together a block of related records in a single domain for a subject. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0441833
UMLS CUI [1,3]
C0600091
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0441833
UMLS CUI [2,3]
C0600091
SDTMIG 3.3
CMGRPID
NCIt V19.10d
C83228
Sponsor-Defined Identifier
Description

Role: Identifier CDISC Notes (for domains) Description (for General Classes): Sponsor-defined reference number. Example: a number pre-printed on the CRF as an explicit line identifier or record identifier defined in the sponsor's operational database. Example: line number on a concomitant medication page. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C2347796
UMLS CUI [1,3]
C0600091
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C2347796
UMLS CUI [2,3]
C0600091
SDTMIG 3.3
CMSPID
NCIt V19.10d
C83075
Reported Name of Drug, Med, or Therapy
Description

Role: Topic CDISC Notes (for domains) Description (for General Classes): Verbatim medication name that is either pre-printed or collected on a CRF. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0027365
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0027365
UMLS CUI [3,1]
C0013227
UMLS CUI [3,2]
C2347852
UMLS CUI [4,1]
C0013227
UMLS CUI [4,2]
C2826257
UMLS CUI [5,1]
C0087111
UMLS CUI [5,2]
C2347852
UMLS CUI [6,1]
C0087111
UMLS CUI [6,2]
C2826257
SDTMIG 3.3
CMTRT
NCIt V19.10d
C70902
Modified Reported Name
Description

Role: Synonym Qualifier CDISC Notes (for domains) Description (for General Classes): If CMTRT is modified to facilitate coding, then CMMODIFY will contain the modified text. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1]
C2826819
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0392747
UMLS CUI [2,3]
C2826302
SDTMIG 3.3
CMMODIFY
NCIt V19.10d
C83229
Standardized Medication Name
Description

Role: Synonym Qualifier CDISC Notes (for domains) Description (for General Classes): Standardized or dictionary-derived text description of CMTRT or CMMODIFY. Equivalent to the generic drug name in WHO Drug. The sponsor is expected to provide the dictionary name and version used to map the terms utilizing the external codelist element in the Define-XML document. If an intervention term does not have a decode value in the dictionary, then CMDECOD will be left blank. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C1442989
UMLS CUI [1,3]
C0027365
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C1442989
UMLS CUI [2,3]
C0027365
SDTMIG 3.3
CMDECOD
NCIt V19.10d
C83345
Category for Medication
Description

Role: Grouping Qualifier CDISC Notes (for domains) Description (for General Classes): Used to define a category of medications/treatment. Examples: "PRIOR", "CONCOMITANT", "ANTI-CANCER MEDICATION", or "GENERAL CONMED". Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C0683312
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C0683312
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMCAT
NCIt V19.10d
C83218
Subcategory for Medication
Description

Role: Grouping Qualifier CDISC Notes (for domains) Description (for General Classes): A further categorization of medications/treatment. Examples: "CHEMOTHERAPY", "HORMONAL THERAPY", "ALTERNATIVE THERAPY". Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C1515010
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C1515010
SDTMIG 3.3
CMSCAT
NCIt V19.10d
C83232
CM Pre-specified
Description

Role: Variable Qualifier CDISC Notes (for domains) Description (for General Classes): Used to indicate whether ("Y"/null) information about the use of a specific medication was solicited on the CRF. Controlled Terms or Format (if applicable): (NY), not extensible

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C2826245
SDTMIG 3.3
CMPRESP
NCIt V19.10d
C113355
CM Occurrence
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): When the use of a specific medication is solicited. CMOCCUR is used to indicate whether or not ("Y"/"N") use of the medication occurred. Values are null for medications not specifically solicited. Controlled Terms or Format (if applicable): (NY)

Data type

text

Alias
UMLS CUI [1,1]
C4284875
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C4284875
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMOCCUR
NCIt V19.10d
C83230
Completion Status
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Used to indicate that a question about the occurrence of a pre-specified intervention was not answered. Should be null or have a value of "NOT DONE". Controlled Terms or Format (if applicable): (ND)

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0805732
UMLS CUI [1,3]
C1522634
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0805732
UMLS CUI [2,3]
C1522634
SDTMIG 3.3
CMSTAT
NCIt V19.10d
C83234
Reason Medication Not Collected
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Reason not done. Used in conjunction with CMSTAT when value is "NOT DONE". Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C2826287
UMLS CUI [1,3]
C1516698
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C2826287
UMLS CUI [2,3]
C1516698
SDTMIG 3.3
CMREASND
NCIt V19.10d
C83231
Indication
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Denotes why a medication was taken or administered. Examples: "NAUSEA", "HYPERTENSION". Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C3146298
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C3146298
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMINDC
NCIt V19.10d
C83085
Medication Class
Description

Role: Variable Qualifier CDISC Notes (for domains) Description (for General Classes): Drug class. May be obtained from coding. When coding to a single class, populate with class value. If using a dictionary and coding to multiple classes, then follow Section 4.2.8.3, Multiple Values for a Non-Result Qualifier Variable, or omit CMCLAS. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0456387
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0456387
SDTMIG 3.3
CMCLAS
NCIt V19.10d
C83219
Medication Class Code
Description

Role: Variable Qualifier CDISC Notes (for domains) Description (for General Classes): Class code corresponding to CMCLAS. Drug class. May be obtained from coding. When coding to a single class, populate with class code. If using a dictionary and coding to multiple classes, then follow Section 4.2.8.3, Multiple Values for a Non-Result Qualifier Variable, or omit CMCLASCD. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0456387
UMLS CUI [1,3]
C0805701
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0456387
UMLS CUI [2,3]
C0805701
SDTMIG 3.3
CMCLASCD
NCIt V19.10d
C83220
Dose per Administration
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Amount of CMTRT given. Not populated when CMDOSTXT is populated. Controlled Terms or Format (if applicable): NA

Data type

float

Alias
UMLS CUI [1,1]
C0178602
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C0178602
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMDOSE
NCIt V19.10d
C83221
Dose Description
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Dosing amounts or a range of dosing information collected in text form. Units may be stored in CMDOSU. Examples: "200-400", "15-20". Not populated when CMDOSE is populated. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2348330
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C2348330
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMDOSTXT
NCIt V19.10d
C83223
Dose Units
Description

Role: Variable Qualifier CDISC Notes (for domains) Description (for General Classes): Units for CMDOSE, CMDOSTOT, or CMDOSTXT. Examples: "ng", "mg", or "mg/kg". Controlled Terms or Format (if applicable): (UNIT), extensible

Data type

text

Alias
UMLS CUI [1,1]
C2348328
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C2348328
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMDOSU
NCIt V19.10d
C83034
Dose Form
Description

Role: Variable Qualifier CDISC Notes (for domains) Description (for General Classes): Dose form for CMTRT. Examples: "TABLET", "LOTION". Controlled Terms or Format (if applicable): (FRM), extensible

Data type

text

Alias
UMLS CUI [1,1]
C0013058
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C0013058
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMDOSFRM
NCIt V19.10d
C83110
Dosing Frequency per Interval
Description

Role: Variable Qualifier CDISC Notes (for domains) Description (for General Classes): Usually expressed as the number of repeated administrations of CMDOSE within a specific time period. Examples: "BID" (twice daily), "Q12H" (every 12 hours). Controlled Terms or Format (if applicable): (FREQ), extensible

Data type

text

Alias
UMLS CUI [1,1]
C2982514
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C2982514
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMDOSFRQ
NCIt V19.10d
C83042
Total Daily Dose
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Total daily dose of CMTRT using the units in CMDOSU. Used when dosing is collected as Total Daily Dose. Total dose over a period other than day could be recorded in a separate Supplemental Qualifier variable. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2348070
UMLS CUI [1,2]
C0439810
UMLS CUI [1,3]
C2347852
UMLS CUI [2,1]
C2348070
UMLS CUI [2,2]
C0439810
UMLS CUI [2,3]
C2826257
SDTMIG 3.3
CMDOSTOT
NCIt V19.10d
C83025
Intended Dose Regimen
Description

Role: Variable Qualifier CDISC Notes (for domains) Description (for General Classes): Text description of the (intended) schedule or regimen for the Intervention. Example: "TWO WEEKS ON, TWO WEEKS OFF". Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C1283828
UMLS CUI [1,2]
C2348331
UMLS CUI [1,3]
C2347852
UMLS CUI [2,1]
C1283828
UMLS CUI [2,2]
C2348331
UMLS CUI [2,3]
C2826257
SDTMIG 3.3
CMDOSRGM
NCIt V19.10d
C83222
Route of Administration
Description

Role: Variable Qualifier CDISC Notes (for domains) Description (for General Classes): Route of administration for the intervention. Examples: "ORAL", "INTRAVENOUS". Controlled Terms or Format (if applicable): (ROUTE), extensible

Data type

text

Alias
UMLS CUI [1,1]
C0013153
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C0013153
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMROUTE
NCIt V19.10d
C83120
Reason for Dose Adjustment
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Describes reason or explanation of why a dose is adjusted. Examples: "ADVERSE EVENT", "INSUFFICIENT RESPONSE", "NON-MEDICAL REASON". Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2826286
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C2826286
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMADJ
NCIt V19.10d
C82555
Reason the Intervention Was Discontinued
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): When dosing of a treatment is recorded over multiple successive records, this variable is applicable only for the (chronologically) last record for the treatment. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0558681
UMLS CUI [1,3]
C2347852
UMLS CUI [2,1]
C0392360
UMLS CUI [2,2]
C0558681
UMLS CUI [2,3]
C2826257
SDTMIG 3.3
CMRSDISC
Planned Order of Element within Arm
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Number that gives the planned order of the Element within the Arm for the Element in which the medication administration started. Null for medications that started before study participation. Controlled Terms or Format (if applicable): NA

Data type

integer

Alias
UMLS CUI [1,1]
C1301732
UMLS CUI [1,2]
C1705175
UMLS CUI [1,3]
C3812827
UMLS CUI [1,4]
C1522541
SDTMIG 3.3
TAETORD
NCIt V19.10d
C83438
Epoch
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Epoch associated with the start date/time of the medication administration. Null for medications that started before study participation. Controlled Terms or Format (if applicable): (EPOCH), extensible

Data type

text

Alias
UMLS CUI [1]
C2347803
SDTMIG 3.3
EPOCH
NCIt V19.10d
C71738
Start Date/Time of Medication
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Start date/time of the medication administration represented in ISO 8601 character format. Controlled Terms or Format (if applicable): ISO 8601

Data type

datetime

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C0808070
UMLS CUI [2,2]
C2826257
UMLS CUI [3,1]
C1301880
UMLS CUI [3,2]
C2347852
UMLS CUI [4,1]
C1301880
UMLS CUI [4,2]
C2826257
SDTMIG 3.3
CMSTDTC
NCIt V19.10d
C83235
End Date/Time of Medication
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): End date/time of the medication administration represented in ISO 8601 character format. Controlled Terms or Format (if applicable): ISO 8601

Data type

datetime

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C0806020
UMLS CUI [2,2]
C2826257
UMLS CUI [3,1]
C1522314
UMLS CUI [3,2]
C2347852
UMLS CUI [4,1]
C1522314
UMLS CUI [4,2]
C2826257
SDTMIG 3.3
CMENDTC
NCIt V19.10d
C83225
Study Day of Start of Medication
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Study day of start of medication relative to the sponsor-defined RFSTDTC. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2826182
UMLS CUI [1,2]
C0439659
UMLS CUI [1,3]
C2347852
UMLS CUI [2,1]
C2826182
UMLS CUI [2,2]
C0439659
UMLS CUI [2,3]
C2826257
SDTMIG 3.3
CMSTDY
NCIt V19.10d
C83236
Study Day of End of Medication
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Study day of end of medication relative to the sponsor-defined RFSTDTC. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2826182
UMLS CUI [1,2]
C0444930
UMLS CUI [1,3]
C2347852
UMLS CUI [2,1]
C2826182
UMLS CUI [2,2]
C0444930
UMLS CUI [2,3]
C2826257
SDTMIG 3.3
CMENDY
NCIt V19.10d
C83226
Duration
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Collected duration for a treatment episode. Used only if collected on the CRF and not derived from start and end date/times. Controlled Terms or Format (if applicable): ISO 8601

Data type

durationDatetime

Alias
UMLS CUI [1,1]
C0449238
UMLS CUI [1,2]
C2347852
UMLS CUI [2,1]
C0449238
UMLS CUI [2,2]
C2826257
SDTMIG 3.3
CMDUR
NCIt V19.10d
C83224
Start Relative to Reference Period
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Describes the start of the medication relative to sponsor-defined reference period. The sponsor-defined reference period is a continuous period of time defined by a discrete starting point and a discrete ending point (represented by RFSTDTC and RFENDTC in Demographics). If information such as "PRIOR" was collected, this information may be translated into CMSTRF. Not all values of the codelist are allowable for this variable. See Section 4.4.7, Use of Relative Timing Variables. Controlled Terms or Format (if applicable): (STENRF), not extensible

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0439659
UMLS CUI [1,3]
C0439564
UMLS CUI [1,4]
C1709877
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0439659
UMLS CUI [2,3]
C0439564
UMLS CUI [2,4]
C1709877
SDTMIG 3.3
CMSTRF
NCIt V19.10d
C83237
End Relative to Reference Period
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Describes the end of the medication relative to the sponsor-defined reference period. The sponsor-defined reference period is a continuous period of time defined by a discrete starting point and a discrete ending point (represented by RFSTDTC and RFENDTC in Demographics). If information such as "PRIOR", "ONGOING, or "CONTINUING" was collected, this information may be translated into CMENRF. Not all values of the codelist are allowable for this variable. See Section 4.4.7, Use of Relative Timing Variables. Controlled Terms or Format (if applicable): (STENRF), not extensible

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0444930
UMLS CUI [1,3]
C0439564
UMLS CUI [1,4]
C1709877
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0444930
UMLS CUI [2,3]
C0439564
UMLS CUI [2,4]
C1709877
SDTMIG 3.3
CMENRF
NCIt V19.10d
C83227
Start Relative to Reference Time Point
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Identifies the start of the medication as being before or after the sponsor-defined reference time point defined by variable CMSTTPT. Not all values of the codelist are allowable for this variable. See Section 4.4.7, Use of Relative Timing Variables. Controlled Terms or Format (if applicable): (STENRF), not extensible

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0439659
UMLS CUI [1,3]
C0439564
UMLS CUI [1,4]
C1709877
UMLS CUI [1,5]
C2348792
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0439659
UMLS CUI [2,3]
C0439564
UMLS CUI [2,4]
C1709877
UMLS CUI [2,5]
C2348792
SDTMIG 3.3
CMSTRTPT
NCIt V19.10d
C87864
Start Reference Time Point
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Description or date/time in ISO 8601 character format of the sponsor-defined reference point referred to by CMSTRTPT. Examples: "2003-12-15" or "VISIT 1". Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0439659
UMLS CUI [1,3]
C1709877
UMLS CUI [1,4]
C2348792
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0439659
UMLS CUI [2,3]
C1709877
UMLS CUI [2,4]
C2348792
SDTMIG 3.3
CMSTTPT
NCIt V19.10d
C87865
End Relative to Reference Time Point
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Identifies the end of the medication as being before or after the sponsor-defined reference time point defined by variable CMENTPT. Not all values of the codelist are allowable for this variable. See Section 4.4.7, Use of Relative Timing Variables. Controlled Terms or Format (if applicable): (STENRF), not extensible

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0444930
UMLS CUI [1,3]
C0439564
UMLS CUI [1,4]
C1709877
UMLS CUI [1,5]
C2348792
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0444930
UMLS CUI [2,3]
C0439564
UMLS CUI [2,4]
C1709877
UMLS CUI [2,5]
C2348792
SDTMIG 3.3
CMENRTPT
NCIt V19.10d
C87862
End Reference Time Point
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Description or date/time in ISO 8601 character format of the sponsor-defined reference point referred to by CMENRTPT. Examples: "2003-12-25" or "VISIT 2". Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0444930
UMLS CUI [1,3]
C1709877
UMLS CUI [1,4]
C2348792
UMLS CUI [2,1]
C2826257
UMLS CUI [2,2]
C0444930
UMLS CUI [2,3]
C1709877
UMLS CUI [2,4]
C2348792
SDTMIG 3.3
CMENTPT
NCIt V19.10d
C87863

Similar models

Observation Class: Interventions - Domain: Concomitant/Prior Medications

  1. StudyEvent: ODM
    1. Observation Class: Special Purpose - Domain: Comments
    2. Observation Class: Special Purpose - Domain: Demographics
    3. Observation Class: Special Purpose - Domain: Subject Elements
    4. Observation Class: Special Purpose - Domain: Subject Disease Milestones
    5. Observation Class: Special Purpose - Domain: Subject Visits
    6. Observation Class: Interventions - Domain: Procedure Agents
    7. Observation Class: Interventions - Domain: Concomitant/Prior Medications
    8. Observation Class: Interventions - Domain: Exposure
    9. Observation Class: Interventions - Domain: Exposure as Collected
    10. Observation Class: Interventions - Domain: Meal Data
    11. Observation Class: Interventions - Domain: Procedures
    12. Observation Class: Interventions - Domain: Substance Use
    13. Observation Class: Events - Domain: Adverse Events
    14. Observation Class: Events - Domain: Clinical Events
    15. Observation Class: Events - Domain: Disposition
    16. Observation Class: Events - Domain: Protocol Deviations
    17. Observation Class: Events - Domain: Healthcare Encounters
    18. Observation Class: Events - Domain: Medical History
    19. Observation Class: Findings - Domain: Drug Accountability
    20. Observation Class: Findings - Domain: Death Details
    21. Observation Class: Findings - Domain: ECG Test Results
    22. Observation Class: Findings - Domain: Inclusion/Exclusion Criteria Not Met
    23. Observation Class: Findings - Domain: Immunogenicity Specimen Assessments
    24. Observation Class: Findings - Domain: Laboratory Test Results
    25. Observation Class: Findings - Domain: Microbiology Specimen
    26. Observation Class: Findings - Domain: Microbiology Susceptibility
    27. Observation Class: Findings - Domain: Microscopic Findings
    28. Observation Class: Findings - Domain: Morphology
    29. Observation Class: Findings - Domain: Cardiovascular System Findings
    30. Observation Class: Findings - Domain: Musculoskeletal System Findings
    31. Observation Class: Findings - Domain: Nervous System Findings
    32. Observation Class: Findings - Domain: Ophthalmic Examinations
    33. Observation Class: Findings - Domain: Reproductive System Findings
    34. Observation Class: Findings - Domain: Respiratory System Findings
    35. Observation Class: Findings - Domain: Urinary System Findings
    36. Observation Class: Findings - Domain: Pharmacokinetics Concentrations
    37. Observation Class: Findings - Domain: Pharmacokinetics Parameters
    38. Observation Class: Findings - Domain: Physical Examination
    39. Observation Class: Findings - Domain: Functional Tests
    40. Observation Class: Findings - Domain: Questionnaires
    41. Observation Class: Findings - Domain: Disease Response and Clin Classification
    42. Observation Class: Findings - Domain: Subject Characteristics
    43. Observation Class: Findings - Domain: Subject Status
    44. Observation Class: Findings - Domain: Tumor/Lesion Identification
    45. Observation Class: Findings - Domain: Tumor/Lesion Results
    46. Observation Class: Findings - Domain: Vital Signs
    47. Observation Class: Findings - Domain: Findings About Events or Interventions
    48. Observation Class: Findings - Domain: Skin Response
    49. Observation Class: Trial Design - Domain: Trial Arms
    50. Observation Class: Trial Design - Domain: Trial Elements
    51. Observation Class: Trial Design - Domain: Trial Visits
    52. Observation Class: Trial Design - Domain: Trial Disease Assessments
    53. Observation Class: Trial Design - Domain: Trial Disease Milestones
    54. Observation Class: Trial Design - Domain: Trial Inclusion/Exclusion Criteria
    55. Observation Class: Trial Design - Domain: Trial Summary Information
    56. Observation Class: Relationships - Domain: Related Records
    57. Observation Class: Relationships - Domain: Supplemental Qualifiers for [domain name]
    58. Observation Class: Relationships - Domain: Related Subjects
    59. Observation Class: Study Reference - Domain: Non-host Organism Identifiers
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Concomitant/Prior Medications
CM (SDTMIG v3.3)
C2347852 (UMLS CUI-1)
C2826257 (UMLS CUI-2)
C49568 (NCIt V19.10d:)
STUDYID
Item
Study Identifier
text
C2826693 (UMLS CUI [1])
STUDYID (SDTMIG 3.3)
C83082 (NCIt V19.10d)
DOMAIN
Item
Domain Abbreviation
text
C1883204 (UMLS CUI [1,1])
C0000723 (UMLS CUI [1,2])
DOMAIN (SDTMIG 3.3)
C49556 (NCIt V19.10d)
USUBJID
Item
Unique Subject Identifier
text
C1710548 (UMLS CUI [1,1])
C2826693 (UMLS CUI [1,2])
USUBJID (SDTMIG 3.3)
C70731 (NCIt V19.10d)
SEQ
Item
Sequence Number
integer
C2347852 (UMLS CUI [1,1])
C2348184 (UMLS CUI [1,2])
C2826257 (UMLS CUI [2,1])
C2348184 (UMLS CUI [2,2])
CMSEQ (SDTMIG 3.3)
C83233 (NCIt V19.10d)
GRPID
Item
Group ID
text
C2347852 (UMLS CUI [1,1])
C0441833 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,3])
C2826257 (UMLS CUI [2,1])
C0441833 (UMLS CUI [2,2])
C0600091 (UMLS CUI [2,3])
CMGRPID (SDTMIG 3.3)
C83228 (NCIt V19.10d)
SPID
Item
Sponsor-Defined Identifier
text
C2347852 (UMLS CUI [1,1])
C2347796 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,3])
C2826257 (UMLS CUI [2,1])
C2347796 (UMLS CUI [2,2])
C0600091 (UMLS CUI [2,3])
CMSPID (SDTMIG 3.3)
C83075 (NCIt V19.10d)
TRT
Item
Reported Name of Drug, Med, or Therapy
text
C2347852 (UMLS CUI [1,1])
C0027365 (UMLS CUI [1,2])
C2826257 (UMLS CUI [2,1])
C0027365 (UMLS CUI [2,2])
C0013227 (UMLS CUI [3,1])
C2347852 (UMLS CUI [3,2])
C0013227 (UMLS CUI [4,1])
C2826257 (UMLS CUI [4,2])
C0087111 (UMLS CUI [5,1])
C2347852 (UMLS CUI [5,2])
C0087111 (UMLS CUI [6,1])
C2826257 (UMLS CUI [6,2])
CMTRT (SDTMIG 3.3)
C70902 (NCIt V19.10d)
MODIFY
Item
Modified Reported Name
text
C2826819 (UMLS CUI [1])
C2826257 (UMLS CUI [2,1])
C0392747 (UMLS CUI [2,2])
C2826302 (UMLS CUI [2,3])
CMMODIFY (SDTMIG 3.3)
C83229 (NCIt V19.10d)
DECOD
Item
Standardized Medication Name
text
C2347852 (UMLS CUI [1,1])
C1442989 (UMLS CUI [1,2])
C0027365 (UMLS CUI [1,3])
C2826257 (UMLS CUI [2,1])
C1442989 (UMLS CUI [2,2])
C0027365 (UMLS CUI [2,3])
CMDECOD (SDTMIG 3.3)
C83345 (NCIt V19.10d)
CAT
Item
Category for Medication
text
C0683312 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C0683312 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMCAT (SDTMIG 3.3)
C83218 (NCIt V19.10d)
SCAT
Item
Subcategory for Medication
text
C2347852 (UMLS CUI [1,1])
C1515010 (UMLS CUI [1,2])
C2826257 (UMLS CUI [2,1])
C1515010 (UMLS CUI [2,2])
CMSCAT (SDTMIG 3.3)
C83232 (NCIt V19.10d)
Item
CM Pre-specified
text
C2347852 (UMLS CUI [1,1])
C2826245 (UMLS CUI [1,2])
CMPRESP (SDTMIG 3.3)
C113355 (NCIt V19.10d)
Code List
CM Pre-specified
CL Item
No (N)
CL Item
NA; Not Applicable (NA)
CL Item
U; UNK; Unknown (U)
CL Item
Yes (Y)
Item
CM Occurrence
text
C4284875 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C4284875 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMOCCUR (SDTMIG 3.3)
C83230 (NCIt V19.10d)
Code List
CM Occurrence
CL Item
No (N)
CL Item
NA; Not Applicable (NA)
CL Item
U; UNK; Unknown (U)
CL Item
Yes (Y)
STAT
Item
Completion Status
text
C2347852 (UMLS CUI [1,1])
C0805732 (UMLS CUI [1,2])
C1522634 (UMLS CUI [1,3])
C2826257 (UMLS CUI [2,1])
C0805732 (UMLS CUI [2,2])
C1522634 (UMLS CUI [2,3])
CMSTAT (SDTMIG 3.3)
C83234 (NCIt V19.10d)
REASND
Item
Reason Medication Not Collected
text
C2347852 (UMLS CUI [1,1])
C2826287 (UMLS CUI [1,2])
C1516698 (UMLS CUI [1,3])
C2826257 (UMLS CUI [2,1])
C2826287 (UMLS CUI [2,2])
C1516698 (UMLS CUI [2,3])
CMREASND (SDTMIG 3.3)
C83231 (NCIt V19.10d)
INDC
Item
Indication
text
C3146298 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C3146298 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMINDC (SDTMIG 3.3)
C83085 (NCIt V19.10d)
CLAS
Item
Medication Class
text
C2347852 (UMLS CUI [1,1])
C0456387 (UMLS CUI [1,2])
C2826257 (UMLS CUI [2,1])
C0456387 (UMLS CUI [2,2])
CMCLAS (SDTMIG 3.3)
C83219 (NCIt V19.10d)
CLASCD
Item
Medication Class Code
text
C2347852 (UMLS CUI [1,1])
C0456387 (UMLS CUI [1,2])
C0805701 (UMLS CUI [1,3])
C2826257 (UMLS CUI [2,1])
C0456387 (UMLS CUI [2,2])
C0805701 (UMLS CUI [2,3])
CMCLASCD (SDTMIG 3.3)
C83220 (NCIt V19.10d)
DOSE
Item
Dose per Administration
float
C0178602 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C0178602 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMDOSE (SDTMIG 3.3)
C83221 (NCIt V19.10d)
DOSTXT
Item
Dose Description
text
C2348330 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C2348330 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMDOSTXT (SDTMIG 3.3)
C83223 (NCIt V19.10d)
Item
Dose Units
text
C2348328 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C2348328 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMDOSU (SDTMIG 3.3)
C83034 (NCIt V19.10d)
Code List
Dose Units
CL Item
Percentage (%)
CL Item
Percent Inhibition (% INHIBITION)
CL Item
Percent Volume per Volume; vol% (%(v/v))
CL Item
Percent Weight per Volume (%(w/v))
CL Item
Percent Weight per Weight (%(w/w))
CL Item
Percent per Minute (%/min)
CL Item
Percent per Second (%/s)
CL Item
Per 100 High Powered Fields (/100 HPFs)
CL Item
Per 100 White Blood Cells (/100 WBC)
CL Item
/10^3 (/10^3)
CL Item
/10^4 (/10^4)
CL Item
/10^5 (/10^5)
CL Item
/200 HPFs (/200 HPFs)
CL Item
/2000 RBC (/2000 RBC)
CL Item
/2500 WBC (/2500 WBC)
CL Item
/4.0 mL (/4.0 mL)
CL Item
/40 HPFs (/40 HPFs)
CL Item
/500 WBC (/500 WBC)
CL Item
/7.5 mL (/7.5 mL)
CL Item
/cmH2O (/cmH2O)
CL Item
Daily (/day)
CL Item
Per Hour (/h)
CL Item
Per High Powered Field (/HPF)
CL Item
/kg (/kg)
CL Item
Per Low Powered Field (/LPF)
CL Item
/Large Square Neubauer (/LSQN)
CL Item
/min (/min)
CL Item
/mm (/mm)
CL Item
/mm2 (/mm2)
CL Item
Every Month; Per Month (/month)
CL Item
1/ms; Reciprocal of Millisecond; ms^-1 (/ms)
CL Item
/sec (/sec)
CL Item
Per Visual Field (/VF)
CL Item
Every week; Per Week; QS (/wk)
CL Item
/(s*kPa) (1/(s*kPa))
CL Item
100 International units/Milliliter (100 IU/mL)
CL Item
10^4/mm3; 10^4/uL; 10^7/mL (10^10/L)
CL Item
10^5/mm3; 10^5/uL; 10^8/mL (10^11/L)
CL Item
TIU/L; Tera International Unit per Liter (10^12 IU/L)
CL Item
/pL; 1/pL; 10^6/mm3; 10^6/uL; T/L; TI/L; Tera/L (10^12/L)
CL Item
Thousand CFU; Thousand Colony Forming Units (10^3 CFU)
CL Item
Thousand CFU/g; Thousand Colony Forming Units per Gram (10^3 CFU/g)
CL Item
Thousand CFU/mL; Thousand Colony Forming Units per Milliliter (10^3 CFU/mL)
CL Item
10^3 copies/mL (10^3 copies/mL)
CL Item
10^3 DNA copies/mL (10^3 DNA copies/mL)
CL Item
Thousand Organisms (10^3 organisms)
CL Item
Thousand Organisms per Gram; Thousand Organisms/g (10^3 organisms/g)
CL Item
Thousand Organisms per Milliliter; Thousand Organisms/mL (10^3 organisms/mL)
CL Item
10^3 RNA copies/mL (10^3 RNA copies/mL)
CL Item
10^3/hpf (10^3/hpf)
CL Item
/mL; 1/mL (10^3/L)
CL Item
Ten Thousand CFU; Ten Thousand Colony Forming Units (10^4 CFU)
CL Item
10^4/hpf (10^4/hpf)
CL Item
10^4/L (10^4/L)
CL Item
10^5/hpf (10^5/hpf)
CL Item
10^2/mL (10^5/L)
CL Item
Million CFU; Million Colony Forming Units (10^6 CFU)
CL Item
Million CFU/g; Million Colony Forming Units per Gram (10^6 CFU/g)
CL Item
Million CFU/mL; Million Colony Forming Units per Milliliter (10^6 CFU/mL)
CL Item
10^6 copies/mL (10^6 copies/mL)
CL Item
10^6 DNA copies/mL (10^6 DNA copies/mL)
CL Item
Million IU; Million International Units (10^6 IU)
CL Item
10^6 IU/mL (10^6 IU/mL)
CL Item
Million Organisms (10^6 organisms)
CL Item
Million Organisms per Gram; Million Organisms/g (10^6 organisms/g)
CL Item
Million Organisms per Milligram; Million Organisms/mg (10^6 organisms/mg)
CL Item
Million Organisms per Milliliter; Million Organisms/mL (10^6 organisms/mL)
CL Item
10^6 RNA copies/mL (10^6 RNA copies/mL)
CL Item
Million U; Million Units (10^6 U)
CL Item
10^6/Ejaculate U (10^6/Ejaculate U)
CL Item
/ug; 1/ug; 10^3/mg; 10^9/kg (10^6/g)
CL Item
10^6/hpf (10^6/hpf)
CL Item
/mm3; /uL; 1/mm3; 1/uL; 10^3/mL; M/L; Mega/L (10^6/L)
CL Item
Ten Million CFU; Ten Million Colony Forming Units (10^7 CFU)
CL Item
10^6/dL (10^7/L)
CL Item
10^2/mm3; 10^2/uL; 10^5/mL (10^8/L)
CL Item
Billion CFU; Billion Colony Forming Units (10^9 CFU)
CL Item
Billion CFU/g; Billion Colony Forming Units per Gram (10^9 CFU/g)
CL Item
Billion CFU/mL; Billion Colony Forming Units per Milliliter (10^9 CFU/mL)
CL Item
Billion Organisms (10^9 organisms)
CL Item
Billion Organisms per Gram; Billion Organisms/g (10^9 organisms/g)
CL Item
Billion Organisms per Milligram; Billion Organisms/mg (10^9 organisms/mg)
CL Item
Billion Organisms per Milliliter; Billion Organisms/mL (10^9 organisms/mL)
CL Item
10^9/dose (10^9/dose)
CL Item
/ng; 1/ng; 10^12/kg; 10^3/ug; 10^6/mg (10^9/g)
CL Item
/nL; 1/nL; 10^3/mm3; 10^3/uL; 10^6/mL; G/L; GI/L; Giga per Liter (10^9/L)
CL Item
Absorbance Unit (Absorbance U)
CL Item
Absorbance Unit per Minute (Absorbance U/min)
CL Item
Absorbance U/mL (Absorbance U/mL)
CL Item
Arbitrary Fluorescence Unit (AFU)
CL Item
Attogram (ag)
CL Item
Antigen Unit per Milliliter (AgU/mL)
CL Item
Arithmetic Mean Fluorescence Intensity Unit (aMFI)
CL Item
Attomole (amol)
CL Item
Ampere (amp)
CL Item
Ampule Dosing Unit (AMPULE)
CL Item
Atomic Mass Unit (amu)
CL Item
Anson U (Anson U)
CL Item
Anti-Xa Activity International Unit (anti-Xa IU)
CL Item
Anti-Xa Activity International Unit per Milliliter (anti-Xa IU/mL)
CL Item
Antibody Unit (Antibody Unit)
CL Item
Immunoglobin A Phospholipid Units; [APL'U] (APL U)
CL Item
Immunoglobin A Phospholipid Units per Milliliter (APL U/mL)
CL Item
Application Dosing Unit (APPLICATION)
CL Item
Immunoglobin A Phosphatidylserine Units; Phosphatidylserine IgA Antibody Unit (APS U)
CL Item
Arbitrary U (Arbitrary U)
CL Item
Atmosphere (atm)
CL Item
Allergy Unit per Milliliter (AU/mL)
CL Item
Bag Dosing Unit (BAG)
CL Item
Bar Dosing Unit (BAR)
CL Item
Bioequivalent Allergy Unit (BAU)
CL Item
Bioequivalent Allergy Unit per Milliliter (BAU/mL)
CL Item
Biological Unit per Milliliter (BE/mL)
CL Item
BEAM BREAKS (BEAM BREAKS)
CL Item
Beats per Minute (beats/min)
CL Item
Bel (bel)
CL Item
Biscuit Dosing Unit (BISCUIT)
CL Item
BLOCKS (BLOCKS)
CL Item
Bolus Dosing Unit (BOLUS)
CL Item
Bottle Dosing Unit (BOTTLE)
CL Item
Box Dosing Unit (BOX)
CL Item
BASE PAIRS (BP)
CL Item
Becquerel (Bq)
CL Item
Becquerel per Gram (Bq/g)
CL Item
Becquerel per Kilogram (Bq/kg)
CL Item
Becquerel per Liter (Bq/L)
CL Item
Becquerel per Milligram; Kilobecquerel per Gram; kBq/g (Bq/mg)
CL Item
Becquerel per Milliliter; Kilobecquerel per Liter; kBq/L (Bq/mL)
CL Item
Becquerel per Microgram; Bq/mcg; Bq/ug; Kilobecquerel per Milligram; MBq/g; Megabecquerel per Gram; kBq/mg (Bq/ug)
CL Item
Becquerel per Microliter; Kilobecquerel per Milliliter; MBq/L; Megabecquerel per Liter; kBq/mL (Bq/uL)
CL Item
Breaths per Minute (breaths/min)
CL Item
Bethesda Unit (BU)
CL Item
Bethesda Unit per Milliliter (BU/mL)
CL Item
Degree Celsius (C)
CL Item
Calorie (cal)
CL Item
Can Dosing Unit (CAN)
CL Item
Capful Dosing Unit (CAPFUL)
CL Item
Caplet Dosing Unit (CAPLET)
CL Item
Capsule Dosing Unit; cap (CAPSULE)
CL Item
Cartridge Dosing Unit (CARTRIDGE)
CL Item
50 Percent Cell Culture Infective Dose per Dose (CCID 50/dose)
CL Item
50 Percent Cell Culture Infective Dose per Milliliter (CCID 50/mL)
CL Item
Candela (cd)
CL Item
cd*s/m2 (cd*s/m2)
CL Item
cd/m2 (cd/m2)
CL Item
Colony Forming Unit per Gram (CFU/g)
CL Item
Colony Forming Unit per Milliliter (CFU/mL)
CL Item
Centigram (cg)
CL Item
Centigray (cGy)
CL Item
Curie (Ci)
CL Item
Curie per Gram; Microcurie per Microgram; Millicurie per Milligram; mCi/mg; uCi/ug (Ci/g)
CL Item
Curie per Kilogram; Microcurie per Milligram; Millicurie per Gram; mCi/g; uCi/mg (Ci/kg)
CL Item
Curie per Liter; Microcurie per Microliter; uCi/uL (Ci/L)
CL Item
Curie per Milligram; Millicurie per Microgram; mCi/ug (Ci/mg)
CL Item
Curie per Milliliter (Ci/mL)
CL Item
Ci/mcg; Curie per Microgram (Ci/ug)
CL Item
Ci/mcL; Curie per Microliter (Ci/uL)
CL Item
Cigar Dosing Unit (CIGAR)
CL Item
Cigarette Dosing Unit (CIGARETTE)
CL Item
Centiliter (cL)
CL Item
Centimeter (cm)
CL Item
cm H2O (cm H2O)
CL Item
Centimeters per Minute (cm/min)
CL Item
cm/sec (cm/s)
CL Item
Square Centimeter (cm2)
CL Item
cmH2O*s/mL (cmH2O*s/mL)
CL Item
cmH2O*s2/mL (cmH2O*s2/mL)
CL Item
cmH2O/mL (cmH2O/mL)
CL Item
Centimeter of Mercury (cmHg)
CL Item
Centimole (cmol)
CL Item
Millimoles per Deciliter; mmol/dL (cmol/L)
CL Item
Coat Dosing Unit (COAT)
CL Item
Container Dosing Unit (CONTAINER)
CL Item
copies/mL (copies/mL)
CL Item
copies/ug (copies/ug)
CL Item
copies/uL (copies/uL)
CL Item
Coulomb (Coulomb)
CL Item
Centipoise (cP)
CL Item
Counts per Minute (cpm)
CL Item
10^-2 sec; Centisecond; csec (cs)
CL Item
Cup Dosing Unit (CUP)
CL Item
Grating Cycles per Centimeter; cpcm (cy/cm)
CL Item
Cycle per Minute (cycle/min)
CL Item
Cylinder Dosing Unit (CYLINDER)
CL Item
D Antigen Unit (DAgU)
CL Item
D Antigen Unit per Milliliter (DAgU/mL)
CL Item
Decamole per Liter; Moles per Deciliter; mol/dL (damol/L)
CL Item
DAYS (DAYS)
CL Item
Decibel (dB)
CL Item
DDU (DDU)
CL Item
Degree Unit of Plane Angle (deg)
CL Item
deg/mm (deg/mm)
CL Item
Diopter (DIOPTER)
CL Item
Dip Dosing Unit; Snuff Dosing Unit (DIP)
CL Item
Disk Dosing Unit (DISK)
CL Item
Deciliter (dL)
CL Item
Decimole (dmol)
CL Item
DNA Copies per Milliliter (DNA copies/mL)
CL Item
Disintegrations per Minute (DPM)
CL Item
Disintegrations per Minute per 0.5 Milliliter (dpm/0.5 mL)
CL Item
Disintegrations per Minute per 100 milligrams; dpm/cg (dpm/100mg)
CL Item
Disintegrations per Minute per Milligram (dpm/mg)
CL Item
Disintegrations per Minute per Milliliter (dpm/mL)
CL Item
Dram (dram)
CL Item
Drink Dosing Unit (DRINK)
CL Item
Drip (DROP)
CL Item
Drum Dosing Unit (DRUM)
CL Item
Dyne (dyn)
CL Item
Electrochemiluminescence Unit (ECL unit)
CL Item
EIA value; Enzyme Immunoassay Unit (EIA unit)
CL Item
50 Percent Embryo Infective Dose per Dose (EID 50/dose)
CL Item
50 Percent Embryo Infective Dose per Milliliter (EID 50/mL)
CL Item
Ejaculate U (Ejaculate U)
CL Item
Enzyme-Linked Immunosorbent Assay Unit (ELISA unit)
CL Item
Enzyme-Linked Immunosorbent Assay Unit per Dose (ELISA unit/dose)
CL Item
Enzyme-Linked Immunosorbent Assay Unit per Milliliter (ELISA unit/mL)
CL Item
Enzyme Unit (Enzyme U)
CL Item
Enzyme Unit per Gram of Hemoglobin (Enzyme U/g Hb)
CL Item
Enzyme Unit/L (Enzyme U/L)
CL Item
Enzyme U/m2 (Enzyme U/m2)
CL Item
Equivalent Weight (eq)
CL Item
EU/dL; Ehrlich Units (EU)
CL Item
EVENTS (EVENTS)
CL Item
Degree Fahrenheit (F)
CL Item
Farad (Farad)
CL Item
Fibrinogen Equivalent Units (FEU)
CL Item
Focus-forming Units (FFU)
CL Item
Femtogram (fg)
CL Item
Fingertip Dosing Unit (FINGERTIP UNIT)
CL Item
Fluorescence Intensity Unit; MFI (FIU)
CL Item
Cubic Micrometer; Cubic Micron; Femtoliter; um3 (fL)
CL Item
Femtomole (fmol)
CL Item
Femtomole per Gram (fmol/g)
CL Item
Femtomole per Liter (fmol/L)
CL Item
Femtomoles per Liter per Second (fmol/L/sec)
CL Item
Fluid Ounce Imperial (foz_br)
CL Item
Fluid Ounce US (foz_us)
CL Item
Proportion of 1 (fraction of 1)
CL Item
F/s; FPS; Frames per Second; Frames/sec (Frames/s)
CL Item
Foot (ft)
CL Item
Square Foot (ft2)
CL Item
Standard Cubic Foot (ft3)
CL Item
Gram (g)
CL Item
Gram per Animal (g/animal)
CL Item
Gram per Animal per Day (g/animal/day)
CL Item
Gram per Animal per Week (g/animal/wk)
CL Item
Gram per Cage (g/cage)
CL Item
Gram per Cage per Day (g/cage/day)
CL Item
Gram per Cage per Week (g/cage/wk)
CL Item
Gram per Square Centimeter (g/cm2)
CL Item
g/24h (g/day)
CL Item
Gram per Deciliter; g% (g/dL)
CL Item
mg/mg (g/g)
CL Item
Gram per Gram per Day (g/g/day)
CL Item
Gram per Kilogram; Milligram per Gram; mg/g; ug/mg (g/kg)
CL Item
Gram per Kilogram per Day; Milligram per Gram per Day; mg/g/day (g/kg/day)
CL Item
Gram per Liter; Kilogram per Cubic Meter; Microgram per Microliter; Milligram per Milliliter; g/L; kg/m3; mg/mL; ug/uL (g/L)
CL Item
Gram per Square Meter (g/m2)
CL Item
Gram per Square Meter per Day (g/m2/day)
CL Item
mg/mmol (g/mol)
CL Item
Gauss (Gauss)
CL Item
Gigabecquerel (GBq)
CL Item
GBq/g; Gigabecquerel per Gram; Kilobecquerel per Microgram; MBq/mg; Megabecquerel per Milligram; kBq/ug (GBq/g)
CL Item
Gigabecquerel per Milligram; MBq/mcg; MBq/ug; Megabecquerel per Microgram (GBq/mg)
CL Item
GBq/mcg; Gigabecquerel per Microgram; MBq/ng; Megabecquerel per nanogram (GBq/ug)
CL Item
GE; Genomic Equivalents (genEq)
CL Item
GE/mL; Genomic Equivalents per Milliliter (genEq/mL)
CL Item
GLOBULE (GLOBULE)
CL Item
Geometric Mean Fluorescence Intensity Unit (gMFI)
CL Item
gpELISA unit/mL (gpELISA unit/mL)
CL Item
Immunoglobin G Phospholipid Units; [GPL'U] (GPL U)
CL Item
Immunoglobin G Phospholipid Units per Milliliter (GPL U/mL)
CL Item
Immunoglobin G Phosphatidylserine Units; Phosphatidylserine IgG Antibody Unit (GPS U)
CL Item
Grain (grain)
CL Item
Gravitational Unit (Gravitational Unit)
CL Item
Metric Drop (gtt)
CL Item
Gray (Gy)
CL Item
Gray/Hour (Gy/h)
CL Item
Gray/Minute (Gy/min)
CL Item
h*% (h*%)
CL Item
Henry (Henry)
CL Item
Histamine Equivalent Prick Unit (HEP)
CL Item
Homeopathic Dilution Unit (HOMEOPATHIC DILUTION)
CL Item
HU (Hounsfield Unit)
CL Item
Hours; h; hr (HOURS)
CL Item
Hectopascal (hPa)
CL Item
Cycle per Second; Hertz; cycle/sec (Hz)
CL Item
Hz/sec (Hz/s)
CL Item
Implant Dosing Unit (IMPLANT)
CL Item
Inch (in)
CL Item
Square Inch (in2)
CL Item
Inhalation Dosing Unit (INHALATION)
CL Item
IE; International Unit (IU)
CL Item
IU/day (IU/day)
CL Item
IU/dL (IU/dL)
CL Item
International Unit per Gram (IU/g)
CL Item
IU/g Hb (IU/g Hb)
CL Item
International Unit per Kilogram (IU/kg)
CL Item
International units per Kilogram per Hour (IU/kg/h)
CL Item
IE/L; IU/L; International Unit per Liter; mIU/mL (IU/L)
CL Item
International Unit per Milligram (IU/mg)
CL Item
IE/mL; International Unit per Milliliter; Kilo International Unit per Liter; kIU/L (IU/mL)
CL Item
IU/mmol (IU/mmol)
CL Item
Jar Dosing Unit (JAR)
CL Item
Joule (Joule)
CL Item
Kelvin (K)
CL Item
ka_u/dL (ka_u/dL)
CL Item
Kallikrein Inhibitor Unit (KALLIKREIN INHIBITOR UNIT)
CL Item
Katal (kat)
CL Item
Kilobecquerel (kBq)
CL Item
GBq/L; Gigabecquerel per Liter; Kilobecquerel per Microliter; MBq/mL; Megabecquerel per Milliliter (kBq/uL)
CL Item
Kilogram-Calorie (kcal)
CL Item
kcal/day (kcal/day)
CL Item
Kilodalton; Kilounified Atomic Mass Unit; ku (kDa)
CL Item
KeV; Kiloelectronvolt (keV)
CL Item
Kilogram (kg)
CL Item
kg/cm (kg/cm)
CL Item
Kilogram per Square Centimeter (kg/cm2)
CL Item
Gram per Milliliter; Kilogram per Liter; g/mL; gram/mL; kg/L; mg/uL (kg/L)
CL Item
Kilogram per Square Meter (kg/m2)
CL Item
g/mmol (kg/mol)
CL Item
kilohertz (kHz)
CL Item
Kit Dosing Unit (KIT)
CL Item
Kilo International Unit (kIU)
CL Item
Kilometer (km)
CL Item
Kilometer Per Hour (km/h)
CL Item
Kilonewton per Centimeter Squared; kdyn/cm2 (kN/cm2)
CL Item
Kilopascal (kPa)
CL Item
Pa/mL/sec (kPa/L/sec)
CL Item
10^3 sec; Kilosecond; ksec (ks)
CL Item
Kilo United States Pharmacopeia Unit (kUSP)
CL Item
Liter (L)
CL Item
L/day (L/day)
CL Item
L/h (L/h)
CL Item
(L/h)/m2; L/h/m2 (L/h/m2)
CL Item
L/kg; mL/g (L/kg)
CL Item
Liter per Liter; dL/dL; mL/mL; uL/uL (L/L)
CL Item
L/min (L/min)
CL Item
(L/min)/m2; L/min/m2 (L/min/m2)
CL Item
L/sec (L/s)
CL Item
L/s/kPa (L/s/kPa)
CL Item
Pound (LB)
CL Item
Linear Foot-pound; Linear Pounds Feet; Linear ft*lbf (Linear ft*LB)
CL Item
Lumen (lm)
CL Item
Log10 50 Percent Embryo Infective Dose per Dose (log EID 50/dose)
CL Item
Log10 50 Percent Cell Culture Infective Dose per Dose (log10 CCID 50/dose)
CL Item
log10 CFU/g (log10 CFU/g)
CL Item
log10 CFU/mL (log10 CFU/mL)
CL Item
log10 copies/mL (log10 copies/mL)
CL Item
Log10 Enzyme-Linked Immunosorbent Assay Unit (Log10 ELISA unit)
CL Item
Log10 Enzyme-Linked Immunosorbent Assay Unit per Dose (Log10 ELISA unit/dose)
CL Item
log10 IU/mL (log10 IU/mL)
CL Item
Log10 50 Percent Tissue Culture Infective Dose per Dose (log10 TCID 50/dose)
CL Item
Log10 50 Percent Tissue Culture Infective Dose per Milliliter (log10 TCID 50/mL)
CL Item
Log10 50 Percent Tissue Culture Infective Dose per Microliter (log10 TCID 50/uL)
CL Item
Lozenge Dosing Unit (LOZENGE)
CL Item
Lux (lx)
CL Item
Meter (m)
CL Item
Meter Per Second (m/sec)
CL Item
m/sec2 (m/sec2)
CL Item
Square Meter (m2)
CL Item
Cubic Meter (m3)
CL Item
Minimum Alveolar Concentration 50% (MAC50)
CL Item
Milliampere (mAmp)
CL Item
mAnson U/mL (mAnson U/mL)
CL Item
Megabecquerel (MBq)
CL Item
GBq/mL; Gigabecquerel per Milliliter; MBq/uL; Megabecquerel per Microliter (MBq/uL)
CL Item
Millicurie (mCi)
CL Item
Microcurie per Gram; Millicurie per Kilogram; uCi/g (mCi/kg)
CL Item
Microcurie per Milliliter; Millicurie per Liter; uCi/mL (mCi/L)
CL Item
MFI; Median Fluorescence Intensity Unit (MdFI)
CL Item
Milliequivalent (mEq)
CL Item
Milliequivalents per Day (mEq/day)
CL Item
Milliequivalent per Deciliter (mEq/dL)
CL Item
Milliequivalent Per Gram (mEq/g)
CL Item
Milliequivalent Per Kilogram (mEq/kg)
CL Item
Milliequivalent Per Liter; Millivalent per Liter; mval/L (mEq/L)
CL Item
Milliequivalent per Milliliter (mEq/mL)
CL Item
Milliequivalent per Millimole (mEq/mmol)
CL Item
Milliequivalent Per Microgram; mEq/mcg (mEq/ug)
CL Item
Milliequivalent Per Microliter (mEq/uL)
CL Item
Molecules of Equivalent Soluble Fluorochromes (MESF)
CL Item
Metabolic Equivalent of Task (MET)
CL Item
MET*h (MET*h)
CL Item
MET*min (MET*min)
CL Item
Milligram (mg)
CL Item
Milligram per Animal (mg/animal)
CL Item
mg/cm2 (mg/cm2)
CL Item
mg/day (mg/day)
CL Item
Milligram per Deciliter; mg% (mg/dL)
CL Item
mg/dose (mg/dose)
CL Item
Milligram per Gram per Hour (mg/g/h)
CL Item
Milligram per Gram per Minute (mg/g/min)
CL Item
mg/h (mg/h)
CL Item
Milligram per Kilogram; ug/g (mg/kg)
CL Item
Milligram per Kilogram per Day (mg/kg/day)
CL Item
mg/kg/dose (mg/kg/dose)
CL Item
Milligram per Kilogram per Hour (mg/kg/h)
CL Item
Milligram per Kilogram per Minute (mg/kg/min)
CL Item
Milligram per Kilogram per Week (mg/kg/week)
CL Item
Gram per Cubic Meter; Microgram per Milliliter; Milligram per Liter; g/m3; mcg/mL; mg/L; ng/uL; ug/mL (mg/L)
CL Item
FEU mg/L; mg FEU/L; mg-L-FEU (mg/L FEU)
CL Item
Milligram per Square Meter (mg/m2)
CL Item
Milligram per Square Meter per Day (mg/m2/day)
CL Item
Milligram per Square Meter per Hour (mg/m2/h)
CL Item
Milligram per Square Meter per Minute (mg/m2/min)
CL Item
mg/min (mg/min)
CL Item
Milligram per Milliliter per Minute (mg/mL/min)
CL Item
ug/mmol (mg/mol)
CL Item
mg2/dL2 (mg2/dL2)
CL Item
Milligram Equivalent (mgEq)
CL Item
Megahertz (MHz)
CL Item
International Mile (Mile)
CL Item
Minute (min)
CL Item
Micro-International Unit per milliliter; mIE/L; mIU/L; mcIU/mL; uIU/mL (mIU/L)
CL Item
mJoule/cm2 (mJoule/cm2)
CL Item
Millikatal (mkat)
CL Item
Milliliter; cm3 (mL)
CL Item
mL*cmH2O (mL*cmH2O)
CL Item
mL/(min*100mL) (mL/(min*100mL))
CL Item
mL/100g/min (mL/100g/min)
CL Item
Milliliter per Animal (mL/animal)
CL Item
Milliliter per Animal per Day (mL/animal/day)
CL Item
Milliliter per Animal per Week (mL/animal/wk)
CL Item
mL/beat (mL/beat)
CL Item
Milliliter per Breath (mL/breath)
CL Item
Milliliter per Cage (mL/cage)
CL Item
Milliliter per Cage per Day (mL/cage/day)
CL Item
Milliliter per Cage per Week (mL/cage/wk)
CL Item
Milliliter per Centimeter; dL/m (mL/cm)
CL Item
mL/cm H2O (mL/cm H2O)
CL Item
mL/mL/min (mL/cm3/min)
CL Item
mL/day (mL/day)
CL Item
Milliliters per Deciliter (mL/dL)
CL Item
mL/dose (mL/dose)
CL Item
(L/day)/kg; (mL/day)/g; mL/g/day (mL/g/day)
CL Item
(L/h)/kg; (mL/h)/g; mL/g/h (mL/g/h)
CL Item
(L/min)/kg; (mL/min)//g; mL/g/min (mL/g/min)
CL Item
cc/hr; cm3/h (mL/h)
CL Item
mL/kg (mL/kg)
CL Item
(mL/day)/kg; mL/kg/day (mL/kg/day)
CL Item
(mL/h)/kg; mL/kg/h (mL/kg/h)
CL Item
(mL/min)/kg; mL/kg/min (mL/kg/min)
CL Item
mL/m2 (mL/m2)
CL Item
Milliliter per Square Meter per Day (mL/m2/day)
CL Item
Milliliter per Square Meter per Hour (mL/m2/h)
CL Item
Milliliter per Square Meter per Minute; mL/min/m2 (mL/m2/min)
CL Item
mL/min (mL/min)
CL Item
mL/min/1.73m2 (mL/min/1.73m2)
CL Item
Milliliter per Minute per Torr (mL/min/mmHg)
CL Item
Milliliters per Millimeter of Mercury (mL/mmHg)
CL Item
mL/mmHg/min/L (mL/mmHg/min/L)
CL Item
mL/sec (mL/s)
CL Item
mL/sec/1.73m2 (mL/sec/1.73m2)
CL Item
Millimeter (mm)
CL Item
Millimeters per Two Hours (mm/2h)
CL Item
Millimeter per Hour (mm/h)
CL Item
Millimeters per Minute (mm/min)
CL Item
Millimeters per Second (mm/sec)
CL Item
Square Millimeter (mm2)
CL Item
mm3/mm2/year (mm3/mm2/year)
CL Item
Millimeters of Aluminum Equivalents (mmAL)
CL Item
Millimeter of Mercury (mmHg)
CL Item
Hybrid Resistance Units; Wood Units (mmHg*min/L)
CL Item
mmHg/L/min (mmHg/L/min)
CL Item
Millimeter of Mercury per Second (mmHg/sec)
CL Item
Millimole (mmol)
CL Item
mmol/day (mmol/day)
CL Item
Millimole per Gram (mmol/g)
CL Item
Millimole per Kilogram (mmol/kg)
CL Item
Micromole per Milliliter; Millimole per Liter; Mole per Cubic Meter; mcmol/mL; mmol/L; mol/m3; nmol/uL; umol/mL (mmol/L)
CL Item
mmol/min/kPa (mmol/min/kPa)
CL Item
mmol/min/kPa/L (mmol/min/kPa/L)
CL Item
umol/mmol (mmol/mol)
CL Item
Millimoles per Second; mmol/sec (mmol/s)
CL Item
mmol2/L2 (mmol2/L2)
CL Item
MilliMerck Unit per Milliliter (mMU/mL)
CL Item
Millinewton (mN)
CL Item
MFI; Mean Fluorescence Intensity Unit (MnFI)
CL Item
Mole (mol)
CL Item
mol/day (mol/day)
CL Item
mmol/mg (mol/g)
CL Item
Mole per Liter; mmol/mL; mol/L (mol/L)
CL Item
Mole per Milligram (mol/mg)
CL Item
Mole per Milliliter (mol/mL)
CL Item
Mole per Mole; mmol/mmol (mol/mol)
CL Item
Month (MONTHS)
CL Item
Milliosmole (mOsm)
CL Item
Milliosmole per Kilogram (mOsm/kg)
CL Item
mOsm/L (mOsm/L)
CL Item
Millipascal (mPa)
CL Item
Miles per Hour (mph)
CL Item
Immunoglobin M Phospholipid Units; [MPL'U] (MPL U)
CL Item
Immunoglobin M Phospholipid Units per Milliliter (MPL U/mL)
CL Item
Immunoglobin M Phosphatidylserine Units; Phosphatidylserine IgM Antibody Unit (MPS U)
CL Item
ms/mmHg (ms/mmHg)
CL Item
ms2 (ms2)
CL Item
Millisecond (msec)
CL Item
mU/g (mU/g)
CL Item
uU/mL (mU/L)
CL Item
Millivolt (mV)
CL Item
Millivolt * Minutes (mV*min)
CL Item
uV/msec (mV/sec)
CL Item
Millivolt Squared per Hertz; Millivolt^2/Hertz (mV2/Hz)
CL Item
Nanocurie (nCi)
CL Item
Nebule Dosing Unit (NEBULE)
CL Item
NEEDLE GAUGE (NEEDLE GAUGE)
CL Item
Newton (Newton)
CL Item
NFIU; NIU; Normalized Fluorescence Intensity Unit; Normalized Intensity Unit (NFIU)
CL Item
Nanogram (ng)
CL Item
ng/day (ng/day)
CL Item
Nanogram per Deciliter (ng/dL)
CL Item
Microgram per Cubic Meter; ng/L; pg/mL; ug/m3 (ng/L)
CL Item
ngEq/L (ngEq/L)
CL Item
Nanokatal (nkat)
CL Item
Nanokatal per Liter (nkat/L)
CL Item
Nanoliter (nL)
CL Item
Nanometer (nm)
CL Item
Nanomole (nmol)
CL Item
Nanomoles Bone Collagen Equivalents per Liter (nmol BCE/L)
CL Item
Nanomoles Bone Collagen Equivalents per Millimole (nmol BCE/mmol)
CL Item
Nanomoles Bone Collagen Equivalents per Nanomole (nmol BCE/nmol)
CL Item
nmol/day (nmol/day)
CL Item
nmol/g; pmol/mg; umol/kg (nmol/g)
CL Item
Nanomole per Liter; pmol/mL (nmol/L)
CL Item
pmol/mL/h (nmol/L/h)
CL Item
nmol*min/L; pmol/mL/min (nmol/L/min)
CL Item
Nanomole per Milliliter per Minute (nmol/mL/min)
CL Item
pmol/mmol (nmol/mol)
CL Item
Nanosecond (nsec)
CL Item
Nanounit per Centiliter (nU/cL)
CL Item
OD; OD_Unit; Optical Density Unit (OD Unit)
CL Item
Ohm (ohm)
CL Item
Opsonization Index 50% (OI50)
CL Item
Osmole (osm)
CL Item
Ounce (oz)
CL Item
Poise (P)
CL Item
/Year; Every Year; Per Annum; Per Year (PA)
CL Item
Pascal (Pa)
CL Item
PACK (PACK)
CL Item
Pack Year (Pack Year)
CL Item
Pack Dosing Unit; Package Dosing Unit (PACKAGE)
CL Item
Packet Dosing Unit (PACKET)
CL Item
Patch Dosing Unit (PATCH)
CL Item
Pellet Dosing Unit (PELLET)
CL Item
Plaque Forming Unit (PFU)
CL Item
PFU/animal (PFU/animal)
CL Item
Plaque Forming Unit per Dose (PFU/dose)
CL Item
Plaque Forming Unit per Milliliter (PFU/mL)
CL Item
Picogram (pg)
CL Item
Picogram per Deciliter (pg/dL)
CL Item
fg/mL; pg/L (pg/L)
CL Item
PHERESIS UNIT (PHERESIS UNIT)
CL Item
Pipe Dosing Unit (PIPE)
CL Item
PIXEL (PIXEL)
CL Item
PPCM; Pixels per Centimeter (PIXELS/cm)
CL Item
PPI; Pixels per Inch (PIXELS/in)
CL Item
Picokatal (pkat)
CL Item
Picokatal per Liter (pkat/L)
CL Item
Picoliter (pL)
CL Item
Picometer (pm)
CL Item
Picomole (pmol)
CL Item
pmol/10^10 cells (pmol/10^10 cells)
CL Item
pmol/10^9 cells (pmol/10^9 cells)
CL Item
pmol/day (pmol/day)
CL Item
Picomoles per Deciliter (pmol/dL)
CL Item
nmol/kg; pmol/g (pmol/g)
CL Item
Femtomole per Milliliter; Picomole per Liter; fmol/mL (pmol/L)
CL Item
Picomoles per Liter per Hour (pmol/L/h)
CL Item
Protein Nitrogen Unit per Milliliter (PNU/mL)
CL Item
POINT (POINT)
CL Item
Pouch Dosing Unit (POUCH)
CL Item
Part per Billion (ppb)
CL Item
Part per Million (ppm)
CL Item
Part per Thousand; per mil; per mille; permil (ppth)
CL Item
Parts per Trillion (pptr)
CL Item
Pressor Unit (PRESSOR UNITS)
CL Item
Picosecond (psec)
CL Item
Pounds per Square Inch (psi)
CL Item
British Pint; Imperial Pint (pt_br)
CL Item
US Pint (pt_us)
CL Item
Puff Dosing Unit (PUFF)
CL Item
Quantity Sufficient (QUANTITY SUFFICIENT)
CL Item
Rad (Rad)
CL Item
RATIO (RATIO)
CL Item
RFIU; RIU; Relative Fluorescence Intensity Unit; Relative Fluorescence Unit; Relative Intensity Unit (RFU)
CL Item
Ring Dosing Unit (RING)
CL Item
RNA Copies per Milliliter (RNA copies/mL)
CL Item
Roentgen (Roentgen)
CL Item
Revolution per Minute (rpm)
CL Item
s*kPa (s*kPa)
CL Item
Seconds per Hour; sec/hr (s/h)
CL Item
s^-1(%O2)^-1 (s^-1(%O2)^-1)
CL Item
Sachet dosing unit (SACHET)
CL Item
Standardized Biological Unit per Milliliter (SBE/mL)
CL Item
Standard Cubic Meter (scm)
CL Item
Scoopful Dosing Unit (SCOOPFUL)
CL Item
Second (sec)
CL Item
SFU/10^6 PBMC; Spots/10^6 PBMC (SFC/10^6 PBMC)
CL Item
Shockwave Dosing Unit (Shock Wave)
CL Item
Siemens (Siemens)
CL Item
Spray Dosing Unit (SPRAY)
CL Item
Standardized Quality Unit per Milliliter (SQU/mL)
CL Item
STEPS (STEPS)
CL Item
Strip Dosing Unit (STRIP)
CL Item
Suppository Dosing Unit (SUPPOSITORY)
CL Item
Sievert (Sv)
CL Item
Syringe Dosing Unit (SYRINGE)
CL Item
Tablet Dosing Unit; tab (TABLET)
CL Item
Tampon Dosing Unit (TAMPON)
CL Item
Tablespoon Dosing Unit (Tbsp)
CL Item
50 Percent Tissue Culture Infective Dose per Dose (TCID 50/dose)
CL Item
Tesla (Tesla)
CL Item
titer (titer)
CL Item
Torr (Torr)
CL Item
Trace Dosing Unit (TRACE)
CL Item
TRANSDUCING UNIT (TRANSDUCING UNIT)
CL Item
TRANSDUCING UNIT/mL (TRANSDUCING UNIT/mL)
CL Item
Troche Dosing Unit (TROCHE)
CL Item
Teaspoon Dosing Unit (tsp)
CL Item
Tube Dosing Unit (TUBE)
CL Item
Tuberculin Unit (tuberculin unit)
CL Item
Tuberculin Unit per Milliliter (tuberculin unit/mL)
CL Item
Unit (U)
CL Item
CARR U; Carratelli Unit (U.CARR)
CL Item
U/10^12 RBC (U/10^12 RBC)
CL Item
Unit per Animal (U/animal)
CL Item
Unit per Centiliter (U/cL)
CL Item
Unit per Deciliter (U/dL)
CL Item
Unit per Gram (U/g)
CL Item
U/g Hb (U/g Hb)
CL Item
Unit per Gram per Day (U/g/day)
CL Item
Unit per Gram per Hour (U/g/h)
CL Item
Unit per Gram per Minute (U/g/min)
CL Item
Unit per Kilogram (U/kg)
CL Item
Unit per kilogram per Day (U/kg/day)
CL Item
Unit per Kilogram per Hour (U/kg/h)
CL Item
Unit per Kilogram per Minute (U/kg/min)
CL Item
Unit per Liter; mU/mL (U/L)
CL Item
Unit per Square Meter (U/m2)
CL Item
Unit per Square Meter per Day (U/m2/day)
CL Item
Unit per Square Meter per Hour (U/m2/h)
CL Item
Unit per Square Meter per Minute (U/m2/min)
CL Item
Unit per Milligram (U/mg)
CL Item
Unit per Milliliter (U/mL)
CL Item
Unit per Millimole (U/mmol)
CL Item
Microcurie; mcCi (uCi)
CL Item
Microcurie per Kilogram; mcCi/kg (uCi/kg)
CL Item
Microcurie per Liter; mcCi/L (uCi/L)
CL Item
Microequivalent (uEq)
CL Item
Microequivalent per Liter; Nanoequivalent per Milliliter; nEq/mL (uEq/L)
CL Item
Microgram; mcg (ug)
CL Item
Microgram per Animal (ug/animal)
CL Item
mcg/cm2 (ug/cm2)
CL Item
mcg/day (ug/day)
CL Item
Microgram per Deciliter (ug/dL)
CL Item
ug/dose (ug/dose)
CL Item
Microgram per Gram per Day (ug/g/day)
CL Item
Microgram per Gram per Hour (ug/g/h)
CL Item
Microgram per Gram per Minute (ug/g/min)
CL Item
mcg/h (ug/h)
CL Item
Microgram per Kilogram; mcg/kg; ng/g; pg/mg; ug/kg (ug/kg)
CL Item
Microgram per Kilogram per Day (ug/kg/day)
CL Item
Microgram per Kilogram per Hour (ug/kg/h)
CL Item
Gamma per Kilogram per Minute; Microgram per Kilogram per Minute; gamma/kg/min; mcg/kg/min (ug/kg/min)
CL Item
Microgram per Liter; Milligram per Cubic Meter; Nanogram per Milliliter; mcg/L; mg/m3; ng/mL; ug/L (ug/L)
CL Item
ug/L DDU (ug/L DDU)
CL Item
FEU ug/L; ng/mL FEU; ug FEU/L; ug-L-FEU (ug/L FEU)
CL Item
ng/mL/h (ug/L/h)
CL Item
Microgram per Square Meter (ug/m2)
CL Item
Microgram per Square Meter per Day (ug/m2/day)
CL Item
Microgram per Square Meter per Hour (ug/m2/h)
CL Item
Microgram per Square Meter per Minute (ug/m2/min)
CL Item
mcg/min (ug/min)
CL Item
Microgram per Milliliter per Hour (ug/mL/h)
CL Item
Microgram Equivalent (ugEq)
CL Item
ngEq/mL; ugEq/L (ugEq/L)
CL Item
uIU/dL (uIU/dL)
CL Item
uIU/L (uIU/L)
CL Item
Microkatal; mckat (ukat)
CL Item
mckat/10^12 RBC (ukat/10^12 RBC)
CL Item
Microkatal per Liter; mckat/L (ukat/L)
CL Item
Microliter; mcL; mm3 (uL)
CL Item
uL/dose (uL/dose)
CL Item
(uL/day)/kg; uL/kg/day (uL/kg/day)
CL Item
Microliter per Milliliter; mL/L; mcL/mL (uL/mL)
CL Item
Micron; mcm (um)
CL Item
um/day (um/day)
CL Item
Micrometers per Second; micron/sec; um/sec (um/s)
CL Item
MicroSquare Meter (um2)
CL Item
Micromole; mcmol (umol)
CL Item
mcmol/day (umol/day)
CL Item
umol/dL (umol/dL)
CL Item
umol/h/mmol (umol/h/mmol)
CL Item
umol/kg/min (umol/kg/min)
CL Item
nmol/mL (umol/L)
CL Item
umol/L/h (umol/L/h)
CL Item
umol/L/min (umol/L/min)
CL Item
Micromoles per Liter per Second (umol/L/sec)
CL Item
Micromole per Milligram per Minute (umol/mg/min)
CL Item
mcmol/min (umol/min)
CL Item
nmol/mmol (umol/mol)
CL Item
Microosmole (uOsM)
CL Item
Microsecond (usec)
CL Item
uS (uSiemens)
CL Item
United States Pharmacopeia Unit (USP U)
CL Item
uU/dL (uU/dL)
CL Item
uU/L (uU/L)
CL Item
Microvolt; mcV (uV)
CL Item
Microvolt * Seconds (uV*sec)
CL Item
Volt (V)
CL Item
V/s; Volt per Second (V/sec)
CL Item
volume fraction (v/v)
CL Item
Vector Genomes/dose (vg/dose)
CL Item
Vector Genomes per Kilogram (vg/kg)
CL Item
Vector Genomes/mL (vg/mL)
CL Item
Vial Dosing Unit (VIAL)
CL Item
VIRTUAL PIXEL (VIRTUAL PIXEL)
CL Item
Volume Pixel (VOXEL)
CL Item
Viral Particles/dose (vp/dose)
CL Item
Viral Particles/mL (vp/mL)
CL Item
Wafer Dosing Unit (WAFER)
CL Item
Watt (Watt)
CL Item
V*sec; Volt Second; Volt-second; Weber (Weber)
CL Item
Week (WEEKS)
CL Item
Yard (yd)
CL Item
Year (YEARS)
Item
Dose Form
text
C0013058 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C0013058 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMDOSFRM (SDTMIG 3.3)
C83110 (NCIt V19.10d)
Code List
Dose Form
CL Item
aer (AEROSOL)
CL Item
AEROSOL, FOAM (AEROSOL, FOAM)
CL Item
AEROSOL, METERED (AEROSOL, METERED)
CL Item
AEROSOL, POWDER (AEROSOL, POWDER)
CL Item
AEROSOL, SPRAY (AEROSOL, SPRAY)
CL Item
BAR, CHEWABLE (BAR, CHEWABLE)
CL Item
BEAD (BEAD)
CL Item
BEAD, IMPLANT, EXTENDED RELEASE (BEAD, IMPLANT, EXTENDED RELEASE)
CL Item
BLOCK (BLOCK)
CL Item
CAPLET (CAPLET)
CL Item
cap (CAPSULE)
CL Item
CAPSULE, COATED (CAPSULE, COATED)
CL Item
CAPSULE, COATED PELLETS (CAPSULE, COATED PELLETS)
CL Item
CAPSULE, COATED, EXTENDED RELEASE (CAPSULE, COATED, EXTENDED RELEASE)
CL Item
CAPSULE, DELAYED RELEASE (CAPSULE, DELAYED RELEASE)
CL Item
CAPSULE, DELAYED RELEASE PELLETS (CAPSULE, DELAYED RELEASE PELLETS)
CL Item
CAPSULE, EXTENDED RELEASE (CAPSULE, EXTENDED RELEASE)
CL Item
CAPSULE, FILM COATED, EXTENDED RELEASE (CAPSULE, FILM COATED, EXTENDED RELEASE)
CL Item
CAPSULE, GELATIN COATED (CAPSULE, GELATIN COATED)
CL Item
CAPSULE, HARD, EXTENDED RELEASE (CAPSULE, HARD, EXTENDED RELEASE)
CL Item
CAPSULE, IMMEDIATE RELEASE (CAPSULE, IMMEDIATE RELEASE)
CL Item
CAPSULE, LIQUID FILLED (CAPSULE, LIQUID FILLED)
CL Item
CAPSULE, SOFTGEL, EXTENDED RELEASE (CAPSULE, SOFTGEL, EXTENDED RELEASE)
CL Item
CEMENT (CEMENT)
CL Item
CIGARETTE (CIGARETTE)
CL Item
CLOTH (CLOTH)
CL Item
CONCENTRATE (CONCENTRATE)
CL Item
CONE  (CONE )
CL Item
CORE, EXTENDED RELEASE  (CORE, EXTENDED RELEASE )
CL Item
CREAM  (CREAM )
CL Item
CREAM, AUGMENTED  (CREAM, AUGMENTED )
CL Item
CRYSTAL  (CRYSTAL )
CL Item
CULTURE  (CULTURE )
CL Item
DIAPHRAGM  (DIAPHRAGM )
CL Item
DISC  (DISC )
CL Item
DOUCHE  (DOUCHE )
CL Item
DRESSING  (DRESSING )
CL Item
DRUG DELIVERY SYSTEM  (DRUG DELIVERY SYSTEM )
CL Item
ELIXIR  (ELIXIR )
CL Item
EMULSION  (EMULSION )
CL Item
ENEMA  (ENEMA )
CL Item
EXTRACT  (EXTRACT )
CL Item
FIBER, EXTENDED RELEASE  (FIBER, EXTENDED RELEASE )
CL Item
FILM  (FILM )
CL Item
FILM, EXTENDED RELEASE  (FILM, EXTENDED RELEASE )
CL Item
FILM, SOLUBLE  (FILM, SOLUBLE )
CL Item
FOR SOLUTION  (FOR SOLUTION )
CL Item
FOR SUSPENSION  (FOR SUSPENSION )
CL Item
FOR SUSPENSION, EXTENDED RELEASE  (FOR SUSPENSION, EXTENDED RELEASE )
CL Item
GAS  (GAS )
CL Item
GEL  (GEL )
CL Item
GEL, CHEWABLE Gummie; Gummy (GEL, CHEWABLE Gummie; Gummy)
CL Item
GEL, DENTIFRICE  (GEL, DENTIFRICE )
CL Item
GEL, METERED  (GEL, METERED )
CL Item
GENERATOR  (GENERATOR )
CL Item
GLOBULE  (GLOBULE )
CL Item
GRAFT  (GRAFT )
CL Item
GRANULE  (GRANULE )
CL Item
GRANULE, DELAYED RELEASE  (GRANULE, DELAYED RELEASE )
CL Item
GRANULE, EFFERVESCENT  (GRANULE, EFFERVESCENT )
CL Item
GRANULE, FOR SOLUTION  (GRANULE, FOR SOLUTION )
CL Item
GRANULE, FOR SUSPENSION  (GRANULE, FOR SUSPENSION )
CL Item
GRANULE, FOR SUSPENSION, EXTENDED RELEASE  (GRANULE, FOR SUSPENSION, EXTENDED RELEASE )
CL Item
GUM  (GUM )
CL Item
GUM, CHEWING  (GUM, CHEWING )
CL Item
GUM, RESIN  (GUM, RESIN )
CL Item
IMPLANT  (IMPLANT )
CL Item
INHALANT  (INHALANT )
CL Item
INJECTABLE, LIPOSOMAL  (INJECTABLE, LIPOSOMAL )
CL Item
INJECTION  (INJECTION )
CL Item
INJECTION, EMULSION  (INJECTION, EMULSION )
CL Item
INJECTION, LIPID COMPLEX  (INJECTION, LIPID COMPLEX )
CL Item
INJECTION, POWDER, FOR SOLUTION  (INJECTION, POWDER, FOR SOLUTION )
CL Item
INJECTION, POWDER, FOR SUSPENSION  (INJECTION, POWDER, FOR SUSPENSION )
CL Item
INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE  (INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE )
CL Item
INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION  (INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION )
CL Item
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION  (INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION )
CL Item
INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION  (INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION )
CL Item
INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION, EXTENDED RELEASE  (INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION, EXTENDED RELEASE )
CL Item
INJECTION, SOLUTION  (INJECTION, SOLUTION )
CL Item
INJECTION, SOLUTION, CONCENTRATE  (INJECTION, SOLUTION, CONCENTRATE )
CL Item
INJECTION, SUSPENSION  (INJECTION, SUSPENSION )
CL Item
INJECTION, SUSPENSION, EXTENDED RELEASE  (INJECTION, SUSPENSION, EXTENDED RELEASE )
CL Item
INJECTION, SUSPENSION, LIPOSOMAL  (INJECTION, SUSPENSION, LIPOSOMAL )
CL Item
INJECTION, SUSPENSION, SONICATED  (INJECTION, SUSPENSION, SONICATED )
CL Item
INSERT  (INSERT )
CL Item
INSERT, EXTENDED RELEASE  (INSERT, EXTENDED RELEASE )
CL Item
INTRAUTERINE DEVICE  (INTRAUTERINE DEVICE )
CL Item
IRRIGANT  (IRRIGANT )
CL Item
JELLY  (JELLY )
CL Item
KIT  (KIT )
CL Item
LINER, DENTAL  (LINER, DENTAL )
CL Item
LINIMENT  (LINIMENT )
CL Item
LIPSTICK  (LIPSTICK )
CL Item
LIQUID  (LIQUID )
CL Item
LIQUID, EXTENDED RELEASE  (LIQUID, EXTENDED RELEASE )
CL Item
LOTION  (LOTION )
CL Item
LOTION, AUGMENTED  (LOTION, AUGMENTED )
CL Item
LOTION/SHAMPOO  (LOTION/SHAMPOO )
CL Item
LOZENGE  (LOZENGE )
CL Item
MOUTHWASH  (MOUTHWASH )
CL Item
NOT APPLICABLE  (NOT APPLICABLE )
CL Item
OIL  (OIL )
CL Item
oint (OINTMENT)
CL Item
OINTMENT, AUGMENTED  (OINTMENT, AUGMENTED )
CL Item
PACKING  (PACKING )
CL Item
PASTE  (PASTE )
CL Item
PASTE, DENTIFRICE  (PASTE, DENTIFRICE )
CL Item
PASTILLE  (PASTILLE )
CL Item
PATCH  (PATCH )
CL Item
PATCH, EXTENDED RELEASE  (PATCH, EXTENDED RELEASE )
CL Item
PATCH, EXTENDED RELEASE, ELECTRICALLY CONTROLLED  (PATCH, EXTENDED RELEASE, ELECTRICALLY CONTROLLED )
CL Item
PELLET  (PELLET )
CL Item
PELLET, IMPLANTABLE  (PELLET, IMPLANTABLE )
CL Item
PELLETS, COATED, EXTENDED RELEASE  (PELLETS, COATED, EXTENDED RELEASE )
CL Item
PILL  (PILL )
CL Item
PLASTER  (PLASTER )
CL Item
POULTICE  (POULTICE )
CL Item
POWDER  (POWDER )
CL Item
POWDER, DENTIFRICE  (POWDER, DENTIFRICE )
CL Item
POWDER, FOR SOLUTION  (POWDER, FOR SOLUTION )
CL Item
POWDER, FOR SUSPENSION  (POWDER, FOR SUSPENSION )
CL Item
POWDER, METERED  (POWDER, METERED )
CL Item
RING  (RING )
CL Item
RINSE  (RINSE )
CL Item
SALVE  (SALVE )
CL Item
SHAMPOO  (SHAMPOO )
CL Item
SHAMPOO, SUSPENSION  (SHAMPOO, SUSPENSION )
CL Item
SOAP  (SOAP )
CL Item
SOLID  (SOLID )
CL Item
SOLUTION  (SOLUTION )
CL Item
SOLUTION, CONCENTRATE  (SOLUTION, CONCENTRATE )
CL Item
SOLUTION, FOR SLUSH  (SOLUTION, FOR SLUSH )
CL Item
SOLUTION, GEL FORMING / DROPS  (SOLUTION, GEL FORMING / DROPS )
CL Item
SOLUTION, GEL FORMING, EXTENDED RELEASE  (SOLUTION, GEL FORMING, EXTENDED RELEASE )
CL Item
SOLUTION/ DROPS  (SOLUTION/ DROPS )
CL Item
SPONGE  (SPONGE )
CL Item
SPRAY  (SPRAY )
CL Item
SPRAY, METERED  (SPRAY, METERED )
CL Item
SPRAY, SUSPENSION  (SPRAY, SUSPENSION )
CL Item
STICK  (STICK )
CL Item
STRIP  (STRIP )
CL Item
supp (SUPPOSITORY)
CL Item
SUPPOSITORY, EXTENDED RELEASE  (SUPPOSITORY, EXTENDED RELEASE )
CL Item
susp (SUSPENSION)
CL Item
SUSPENSION, EXTENDED RELEASE  (SUSPENSION, EXTENDED RELEASE )
CL Item
SUSPENSION/DROPS  (SUSPENSION/DROPS )
CL Item
SUTURE  (SUTURE )
CL Item
SWAB  (SWAB )
CL Item
SYRUP  (SYRUP )
CL Item
tab (TABLET)
CL Item
TABLET, CHEWABLE  (TABLET, CHEWABLE )
CL Item
TABLET, COATED  (TABLET, COATED )
CL Item
TABLET, COATED PARTICLES  (TABLET, COATED PARTICLES )
CL Item
TABLET, DELAYED RELEASE Tablet, Gastro-Resistant (TABLET, DELAYED RELEASE Tablet, Gastro-Resistant)
CL Item
TABLET, DELAYED RELEASE PARTICLES  (TABLET, DELAYED RELEASE PARTICLES )
CL Item
TABLET, EFFERVESCENT  (TABLET, EFFERVESCENT )
CL Item
TABLET, EXTENDED RELEASE Tablet, Prolonged Release (TABLET, EXTENDED RELEASE Tablet, Prolonged Release)
CL Item
TABLET, FILM COATED  (TABLET, FILM COATED )
CL Item
TABLET, FILM COATED, EXTENDED RELEASE  (TABLET, FILM COATED, EXTENDED RELEASE )
CL Item
TABLET, FOR SOLUTION  (TABLET, FOR SOLUTION )
CL Item
TABLET, FOR SUSPENSION  (TABLET, FOR SUSPENSION )
CL Item
TABLET, IMMEDIATE RELEASE  (TABLET, IMMEDIATE RELEASE )
CL Item
TABLET, IMMEDIATE RELEASE, SOLID DISPERSION  (TABLET, IMMEDIATE RELEASE, SOLID DISPERSION )
CL Item
TABLET, MULTILAYER  (TABLET, MULTILAYER )
CL Item
TABLET, MULTILAYER, EXTENDED RELEASE  (TABLET, MULTILAYER, EXTENDED RELEASE )
CL Item
TABLET, ORALLY DISINTEGRATING  (TABLET, ORALLY DISINTEGRATING )
CL Item
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE  (TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE )
CL Item
TABLET, SOLUBLE  (TABLET, SOLUBLE )
CL Item
TABLET, SUGAR COATED  (TABLET, SUGAR COATED )
CL Item
TAMPON  (TAMPON )
CL Item
TAPE  (TAPE )
CL Item
TINCTURE  (TINCTURE )
CL Item
TROCHE  (TROCHE )
CL Item
UNASSIGNED  (UNASSIGNED )
CL Item
UNKNOWN  (UNKNOWN )
CL Item
WAFER (WAFER)
Item
Dosing Frequency per Interval
text
C2982514 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C2982514 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMDOSFRQ (SDTMIG 3.3)
C83042 (NCIt V19.10d)
Code List
Dosing Frequency per Interval
CL Item
One Time Per Week (1 TIME PER WEEK)
CL Item
10 Days Monthly (10 DAYS PER MONTH)
CL Item
BIS; Twice per week (2 TIMES PER WEEK)
CL Item
2 Times Per Year (2 TIMES PER YEAR)
CL Item
3 Times Per Month (3 TIMES PER MONTH)
CL Item
TIS; Three times a week (3 TIMES PER WEEK)
CL Item
3 Times Per Year (3 TIMES PER YEAR)
CL Item
4 Times Per Month (4 TIMES PER MONTH)
CL Item
4 times per week; QIS (4 TIMES PER WEEK)
CL Item
4 Times Per Year (4 TIMES PER YEAR)
CL Item
5 Times Daily (5 TIMES PER DAY)
CL Item
5 Times Per Month (5 TIMES PER MONTH)
CL Item
5 Times Per Week (5 TIMES PER WEEK)
CL Item
5 Times Per Year (5 TIMES PER YEAR)
CL Item
6 Times Daily (6 TIMES PER DAY)
CL Item
6 Times Per Month (6 TIMES PER MONTH)
CL Item
6 Times Per Week (6 TIMES PER WEEK)
CL Item
6 Times Per Year (6 TIMES PER YEAR)
CL Item
7 Times Daily (7 TIMES PER DAY)
CL Item
7 Times Per Week (7 TIMES PER WEEK)
CL Item
8 Times Daily (8 TIMES PER DAY)
CL Item
9 Times Daily (9 TIMES PER DAY)
CL Item
Ad Libitum (AD LIBITUM)
CL Item
BD; Twice per day (BID)
CL Item
Twice per month (BIM)
CL Item
Continuous (CONTINUOUS)
CL Item
Q12S (EVERY 12 WEEKS)
CL Item
Q16S (EVERY 16 WEEKS)
CL Item
Every 2 weeks; Q2S (EVERY 2 WEEKS)
CL Item
Every 3 weeks; Q3S (EVERY 3 WEEKS)
CL Item
EVERY 3 YEARS (EVERY 3 YEARS)
CL Item
Every 4 weeks; Q4S (EVERY 4 WEEKS)
CL Item
Every 5 weeks; Q5S (EVERY 5 WEEKS)
CL Item
EVERY 5 YEARS (EVERY 5 YEARS)
CL Item
Every 6 Weeks; Q6S (EVERY 6 WEEKS)
CL Item
Every 7 weeks; Q7S (EVERY 7 WEEKS)
CL Item
Every 8 weeks; Q8S (EVERY 8 WEEKS)
CL Item
EVERY AFTERNOON (EVERY AFTERNOON)
CL Item
EVERY EVENING (EVERY EVENING)
CL Item
Every week; Per Week; QS (EVERY WEEK)
CL Item
Intermittent (INTERMITTENT)
CL Item
Occasional (OCCASIONAL)
CL Item
ONCE (ONCE)
CL Item
/Year; Every Year; Per Annum; Per Year (PA)
CL Item
As needed (PRN)
CL Item
Every 10 hours (Q10H)
CL Item
Every 11 hours (Q11H)
CL Item
Every 12 hours (Q12H)
CL Item
Every 13 hours (Q13H)
CL Item
Every 14 hours (Q14H)
CL Item
Every 15 hours (Q15H)
CL Item
Every 16 hours (Q16H)
CL Item
Every 17 hours (Q17H)
CL Item
Every 18 hours (Q18H)
CL Item
Every 19 hours (Q19H)
CL Item
Every 20 hours (Q20H)
CL Item
Every 21 hours (Q21H)
CL Item
Every 22 hours (Q22H)
CL Item
Every 23 hours (Q23H)
CL Item
Every 24 hours (Q24H)
CL Item
Every 2 hours (Q2H)
CL Item
Every two months (Q2M)
CL Item
Every 36 Hours (Q36H)
CL Item
Every 3 days (Q3D)
CL Item
Every 3 hours (Q3H)
CL Item
Every 3 months (Q3M)
CL Item
Every 45 Minutes (Q45MIN)
CL Item
Every 48 Hours (Q48H)
CL Item
Every 4 days (Q4D)
CL Item
Every 4 hours (Q4H)
CL Item
Every 4 months (Q4M)
CL Item
Every 5 days (Q5D)
CL Item
Every 5 hours (Q5H)
CL Item
Q6D (Q6D)
CL Item
Every 6 hours (Q6H)
CL Item
Every 6 Months (Q6M)
CL Item
Every 7 Days (Q7D)
CL Item
Every 7 hours (Q7H)
CL Item
Every 8 hours (Q8H)
CL Item
Every 9 hours (Q9H)
CL Item
Every Morning (QAM)
CL Item
Daily (QD)
CL Item
Every hour (QH)
CL Item
QHS (QHS)
CL Item
4 times per day (QID)
CL Item
Every Month; Per Month (QM)
CL Item
QN (QN)
CL Item
Every other day (QOD)
CL Item
QPM (QPM)
CL Item
THRICE (THRICE)
CL Item
3 times per day (TID)
CL Item
TWICE (TWICE)
CL Item
U; UNK; Unknown (UNKNOWN)
DOSTOT
Item
Total Daily Dose
text
C2348070 (UMLS CUI [1,1])
C0439810 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,3])
C2348070 (UMLS CUI [2,1])
C0439810 (UMLS CUI [2,2])
C2826257 (UMLS CUI [2,3])
CMDOSTOT (SDTMIG 3.3)
C83025 (NCIt V19.10d)
DOSRGM
Item
Intended Dose Regimen
text
C1283828 (UMLS CUI [1,1])
C2348331 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,3])
C1283828 (UMLS CUI [2,1])
C2348331 (UMLS CUI [2,2])
C2826257 (UMLS CUI [2,3])
CMDOSRGM (SDTMIG 3.3)
C83222 (NCIt V19.10d)
Item
Route of Administration
text
C0013153 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C0013153 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMROUTE (SDTMIG 3.3)
C83120 (NCIt V19.10d)
Code List
Route of Administration
CL Item
AURICULAR (OTIC)  (AURICULAR (OTIC) )
CL Item
BUCCAL  (BUCCAL )
CL Item
CONJUNCTIVAL  (CONJUNCTIVAL )
CL Item
CUTANEOUS  (CUTANEOUS )
CL Item
DENTAL  (DENTAL )
CL Item
DIETARY  (DIETARY )
CL Item
ELECTRO-OSMOSIS  (ELECTRO-OSMOSIS )
CL Item
Intracervical Route of Administration (ENDOCERVICAL)
CL Item
ENDOSINUSIAL  (ENDOSINUSIAL )
CL Item
Intratracheal Route of Administration (ENDOTRACHEAL)
CL Item
ENTERAL  (ENTERAL )
CL Item
EPIDURAL  (EPIDURAL )
CL Item
EXTRA-AMNIOTIC  (EXTRA-AMNIOTIC )
CL Item
EXTRACORPOREAL  (EXTRACORPOREAL )
CL Item
HEMODIALYSIS  (HEMODIALYSIS )
CL Item
INFILTRATION  (INFILTRATION )
CL Item
INTERSTITIAL  (INTERSTITIAL )
CL Item
INTRA-ABDOMINAL  (INTRA-ABDOMINAL )
CL Item
INTRA-AMNIOTIC  (INTRA-AMNIOTIC )
CL Item
INTRA-ARTERIAL  (INTRA-ARTERIAL )
CL Item
INTRA-ARTICULAR  (INTRA-ARTICULAR )
CL Item
INTRABILIARY  (INTRABILIARY )
CL Item
INTRABRONCHIAL  (INTRABRONCHIAL )
CL Item
INTRABURSAL  (INTRABURSAL )
CL Item
INTRACAMERAL  (INTRACAMERAL )
CL Item
INTRACARDIAC  (INTRACARDIAC )
CL Item
INTRACARTILAGINOUS  (INTRACARTILAGINOUS )
CL Item
INTRACAUDAL  (INTRACAUDAL )
CL Item
INTRACAVERNOUS  (INTRACAVERNOUS )
CL Item
INTRACAVITARY  (INTRACAVITARY )
CL Item
INTRACEREBRAL  (INTRACEREBRAL )
CL Item
INTRACISTERNAL  (INTRACISTERNAL )
CL Item
INTRACORNEAL  (INTRACORNEAL )
CL Item
INTRACORONAL, DENTAL  (INTRACORONAL, DENTAL )
CL Item
INTRACORONARY  (INTRACORONARY )
CL Item
INTRACORPORUS CAVERNOSUM  (INTRACORPORUS CAVERNOSUM )
CL Item
INTRADERMAL  (INTRADERMAL )
CL Item
INTRADISCAL  (INTRADISCAL )
CL Item
INTRADUCTAL  (INTRADUCTAL )
CL Item
INTRADUODENAL  (INTRADUODENAL )
CL Item
INTRADURAL  (INTRADURAL )
CL Item
INTRAEPIDERMAL  (INTRAEPIDERMAL )
CL Item
INTRAESOPHAGEAL  (INTRAESOPHAGEAL )
CL Item
INTRAGASTRIC  (INTRAGASTRIC )
CL Item
INTRAGINGIVAL  (INTRAGINGIVAL )
CL Item
INTRAHEPATIC  (INTRAHEPATIC )
CL Item
INTRAILEAL  (INTRAILEAL )
CL Item
INTRAJEJUNAL  (INTRAJEJUNAL )
CL Item
INTRALESIONAL  (INTRALESIONAL )
CL Item
INTRALUMINAL  (INTRALUMINAL )
CL Item
INTRALYMPHATIC  (INTRALYMPHATIC )
CL Item
INTRAMANDIBULAR  (INTRAMANDIBULAR )
CL Item
INTRAMEDULLARY  (INTRAMEDULLARY )
CL Item
INTRAMENINGEAL  (INTRAMENINGEAL )
CL Item
INTRAMUSCULAR  (INTRAMUSCULAR )
CL Item
INTRANODAL  (INTRANODAL )
CL Item
INTRAOCULAR  (INTRAOCULAR )
CL Item
INTRAOSSEOUS  (INTRAOSSEOUS )
CL Item
INTRAOVARIAN  (INTRAOVARIAN )
CL Item
INTRAPALATAL  (INTRAPALATAL )
CL Item
INTRAPARENCHYMAL  (INTRAPARENCHYMAL )
CL Item
INTRAPERICARDIAL  (INTRAPERICARDIAL )
CL Item
INTRAPERITONEAL  (INTRAPERITONEAL )
CL Item
INTRAPLEURAL  (INTRAPLEURAL )
CL Item
INTRAPROSTATIC  (INTRAPROSTATIC )
CL Item
INTRAPULMONARY  (INTRAPULMONARY )
CL Item
INTRASINAL  (INTRASINAL )
CL Item
INTRASPINAL  (INTRASPINAL )
CL Item
INTRASTOMAL  (INTRASTOMAL )
CL Item
INTRASURGICAL SITE  (INTRASURGICAL SITE )
CL Item
INTRASYNOVIAL  (INTRASYNOVIAL )
CL Item
INTRATENDINOUS  (INTRATENDINOUS )
CL Item
INTRATESTICULAR  (INTRATESTICULAR )
CL Item
INTRATHALAMIC  (INTRATHALAMIC )
CL Item
INTRATHECAL  (INTRATHECAL )
CL Item
INTRATHORACIC  (INTRATHORACIC )
CL Item
INTRATUBULAR  (INTRATUBULAR )
CL Item
Intratumor Route of Administration (INTRATUMOR)
CL Item
INTRATYMPANIC  (INTRATYMPANIC )
CL Item
INTRAUTERINE  (INTRAUTERINE )
CL Item
INTRAVAGINAL  (INTRAVAGINAL )
CL Item
INTRAVASCULAR  (INTRAVASCULAR )
CL Item
INTRAVENOUS  (INTRAVENOUS )
CL Item
INTRAVENOUS BOLUS  (INTRAVENOUS BOLUS )
CL Item
INTRAVENOUS DRIP  (INTRAVENOUS DRIP )
CL Item
INTRAVENTRICULAR  (INTRAVENTRICULAR )
CL Item
INTRAVESICAL  (INTRAVESICAL )
CL Item
INTRAVITREAL  (INTRAVITREAL )
CL Item
IONTOPHORESIS  (IONTOPHORESIS )
CL Item
IRRIGATION  (IRRIGATION )
CL Item
LARYNGEAL  (LARYNGEAL )
CL Item
MICRODIALYSIS  (MICRODIALYSIS )
CL Item
Intranasal Route of Administration (NASAL)
CL Item
NASOGASTRIC  (NASOGASTRIC )
CL Item
NOT APPLICABLE  (NOT APPLICABLE )
CL Item
OCCLUSIVE DRESSING TECHNIQUE  (OCCLUSIVE DRESSING TECHNIQUE )
CL Item
OPHTHALMIC  (OPHTHALMIC )
CL Item
Intraoral Route of Administration; PO (ORAL)
CL Item
ORAL GAVAGE  (ORAL GAVAGE )
CL Item
OROMUCOSAL  (OROMUCOSAL )
CL Item
OROPHARYNGEAL  (OROPHARYNGEAL )
CL Item
PARENTERAL  (PARENTERAL )
CL Item
PERCUTANEOUS  (PERCUTANEOUS )
CL Item
PERIARTICULAR  (PERIARTICULAR )
CL Item
PERIDURAL  (PERIDURAL )
CL Item
PERINEURAL  (PERINEURAL )
CL Item
PERIODONTAL  (PERIODONTAL )
CL Item
PERIVENOUS  (PERIVENOUS )
CL Item
RECTAL  (RECTAL )
CL Item
RESPIRATORY (INHALATION)  (RESPIRATORY (INHALATION) )
CL Item
RETROBULBAR  (RETROBULBAR )
CL Item
SOFT TISSUE  (SOFT TISSUE )
CL Item
SUBARACHNOID  (SUBARACHNOID )
CL Item
SUBCONJUNCTIVAL  (SUBCONJUNCTIVAL )
CL Item
SC; Subdermal Route of Administration (SUBCUTANEOUS)
CL Item
SUBLINGUAL  (SUBLINGUAL )
CL Item
SUBMUCOSAL  (SUBMUCOSAL )
CL Item
SUBRETINAL  (SUBRETINAL )
CL Item
SUBTENON  (SUBTENON )
CL Item
SUPRACHOROIDAL  (SUPRACHOROIDAL )
CL Item
TOP (TOPICAL)
CL Item
TRANSDERMAL  (TRANSDERMAL )
CL Item
TRANSMAMMARY  (TRANSMAMMARY )
CL Item
TRANSMUCOSAL  (TRANSMUCOSAL )
CL Item
TRANSPLACENTAL  (TRANSPLACENTAL )
CL Item
TRANSTRACHEAL  (TRANSTRACHEAL )
CL Item
TRANSTYMPANIC  (TRANSTYMPANIC )
CL Item
UNASSIGNED  (UNASSIGNED )
CL Item
UNKNOWN  (UNKNOWN )
CL Item
URETERAL  (URETERAL )
CL Item
URETHRAL  (URETHRAL )
CL Item
VAGINAL  (VAGINAL )
ADJ
Item
Reason for Dose Adjustment
text
C2826286 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C2826286 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMADJ (SDTMIG 3.3)
C82555 (NCIt V19.10d)
RSDISC
Item
Reason the Intervention Was Discontinued
text
C0392360 (UMLS CUI [1,1])
C0558681 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,3])
C0392360 (UMLS CUI [2,1])
C0558681 (UMLS CUI [2,2])
C2826257 (UMLS CUI [2,3])
CMRSDISC (SDTMIG 3.3)
TAETORD
Item
Planned Order of Element within Arm
integer
C1301732 (UMLS CUI [1,1])
C1705175 (UMLS CUI [1,2])
C3812827 (UMLS CUI [1,3])
C1522541 (UMLS CUI [1,4])
TAETORD (SDTMIG 3.3)
C83438 (NCIt V19.10d)
Item
Epoch
text
C2347803 (UMLS CUI [1])
EPOCH (SDTMIG 3.3)
C71738 (NCIt V19.10d)
Code List
Epoch
CL Item
BASELINE  (BASELINE )
CL Item
BLINDED TREATMENT  (BLINDED TREATMENT )
CL Item
Continuation Phase (CONTINUATION TREATMENT)
CL Item
FOLLOW-UP  (FOLLOW-UP )
CL Item
Induction Phase; Intensive Phase (INDUCTION TREATMENT)
CL Item
LONG-TERM FOLLOW-UP  (LONG-TERM FOLLOW-UP )
CL Item
OPEN LABEL TREATMENT  (OPEN LABEL TREATMENT )
CL Item
RUN-IN  (RUN-IN )
CL Item
SCREENING  (SCREENING )
CL Item
TREATMENT  (TREATMENT )
CL Item
WASHOUT  (WASHOUT )
STDTC
Item
Start Date/Time of Medication
datetime
C0808070 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C0808070 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
C1301880 (UMLS CUI [3,1])
C2347852 (UMLS CUI [3,2])
C1301880 (UMLS CUI [4,1])
C2826257 (UMLS CUI [4,2])
CMSTDTC (SDTMIG 3.3)
C83235 (NCIt V19.10d)
ENDTC
Item
End Date/Time of Medication
datetime
C0806020 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C0806020 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
C1522314 (UMLS CUI [3,1])
C2347852 (UMLS CUI [3,2])
C1522314 (UMLS CUI [4,1])
C2826257 (UMLS CUI [4,2])
CMENDTC (SDTMIG 3.3)
C83225 (NCIt V19.10d)
STDY
Item
Study Day of Start of Medication
text
C2826182 (UMLS CUI [1,1])
C0439659 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,3])
C2826182 (UMLS CUI [2,1])
C0439659 (UMLS CUI [2,2])
C2826257 (UMLS CUI [2,3])
CMSTDY (SDTMIG 3.3)
C83236 (NCIt V19.10d)
ENDY
Item
Study Day of End of Medication
text
C2826182 (UMLS CUI [1,1])
C0444930 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,3])
C2826182 (UMLS CUI [2,1])
C0444930 (UMLS CUI [2,2])
C2826257 (UMLS CUI [2,3])
CMENDY (SDTMIG 3.3)
C83226 (NCIt V19.10d)
DUR
Item
Duration
durationDatetime
C0449238 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C0449238 (UMLS CUI [2,1])
C2826257 (UMLS CUI [2,2])
CMDUR (SDTMIG 3.3)
C83224 (NCIt V19.10d)
Item
Start Relative to Reference Period
text
C2347852 (UMLS CUI [1,1])
C0439659 (UMLS CUI [1,2])
C0439564 (UMLS CUI [1,3])
C1709877 (UMLS CUI [1,4])
C2826257 (UMLS CUI [2,1])
C0439659 (UMLS CUI [2,2])
C0439564 (UMLS CUI [2,3])
C1709877 (UMLS CUI [2,4])
CMSTRF (SDTMIG 3.3)
C83237 (NCIt V19.10d)
Code List
Start Relative to Reference Period
CL Item
AFTER  (AFTER )
CL Item
BEFORE  (BEFORE )
CL Item
COINCItDENT  (COINCItDENT )
CL Item
DURING  (DURING )
CL Item
DURING/AFTER  (DURING/AFTER )
CL Item
Continuous (ONGOING)
CL Item
U; UNK; Unknown (UNKNOWN)
Item
End Relative to Reference Period
text
C2347852 (UMLS CUI [1,1])
C0444930 (UMLS CUI [1,2])
C0439564 (UMLS CUI [1,3])
C1709877 (UMLS CUI [1,4])
C2826257 (UMLS CUI [2,1])
C0444930 (UMLS CUI [2,2])
C0439564 (UMLS CUI [2,3])
C1709877 (UMLS CUI [2,4])
CMENRF (SDTMIG 3.3)
C83227 (NCIt V19.10d)
Code List
End Relative to Reference Period
CL Item
AFTER  (AFTER )
CL Item
BEFORE  (BEFORE )
CL Item
COINCItDENT  (COINCItDENT )
CL Item
DURING  (DURING )
CL Item
DURING/AFTER  (DURING/AFTER )
CL Item
Continuous (ONGOING)
CL Item
U; UNK; Unknown (UNKNOWN)
Item
Start Relative to Reference Time Point
text
C2347852 (UMLS CUI [1,1])
C0439659 (UMLS CUI [1,2])
C0439564 (UMLS CUI [1,3])
C1709877 (UMLS CUI [1,4])
C2348792 (UMLS CUI [1,5])
C2826257 (UMLS CUI [2,1])
C0439659 (UMLS CUI [2,2])
C0439564 (UMLS CUI [2,3])
C1709877 (UMLS CUI [2,4])
C2348792 (UMLS CUI [2,5])
CMSTRTPT (SDTMIG 3.3)
C87864 (NCIt V19.10d)
Code List
Start Relative to Reference Time Point
CL Item
AFTER  (AFTER )
CL Item
BEFORE  (BEFORE )
CL Item
COINCItDENT  (COINCItDENT )
CL Item
DURING  (DURING )
CL Item
DURING/AFTER  (DURING/AFTER )
CL Item
Continuous (ONGOING)
CL Item
U; UNK; Unknown (UNKNOWN)
STTPT
Item
Start Reference Time Point
text
C2347852 (UMLS CUI [1,1])
C0439659 (UMLS CUI [1,2])
C1709877 (UMLS CUI [1,3])
C2348792 (UMLS CUI [1,4])
C2826257 (UMLS CUI [2,1])
C0439659 (UMLS CUI [2,2])
C1709877 (UMLS CUI [2,3])
C2348792 (UMLS CUI [2,4])
CMSTTPT (SDTMIG 3.3)
C87865 (NCIt V19.10d)
Item
End Relative to Reference Time Point
text
C2347852 (UMLS CUI [1,1])
C0444930 (UMLS CUI [1,2])
C0439564 (UMLS CUI [1,3])
C1709877 (UMLS CUI [1,4])
C2348792 (UMLS CUI [1,5])
C2826257 (UMLS CUI [2,1])
C0444930 (UMLS CUI [2,2])
C0439564 (UMLS CUI [2,3])
C1709877 (UMLS CUI [2,4])
C2348792 (UMLS CUI [2,5])
CMENRTPT (SDTMIG 3.3)
C87862 (NCIt V19.10d)
Code List
End Relative to Reference Time Point
CL Item
AFTER  (AFTER )
CL Item
BEFORE  (BEFORE )
CL Item
COINCItDENT  (COINCItDENT )
CL Item
DURING  (DURING )
CL Item
DURING/AFTER  (DURING/AFTER )
CL Item
Continuous (ONGOING)
CL Item
U; UNK; Unknown (UNKNOWN)
ENTPT
Item
End Reference Time Point
text
C2347852 (UMLS CUI [1,1])
C0444930 (UMLS CUI [1,2])
C1709877 (UMLS CUI [1,3])
C2348792 (UMLS CUI [1,4])
C2826257 (UMLS CUI [2,1])
C0444930 (UMLS CUI [2,2])
C1709877 (UMLS CUI [2,3])
C2348792 (UMLS CUI [2,4])
CMENTPT (SDTMIG 3.3)
C87863 (NCIt V19.10d)

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial